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Outline of this thesis
The main goal of this thesis was to search for molecular prognostic and predictive 
markers of response to therapy in stage II and III sporadic colon carcinoma. 
This thesis has two main parts: One corresponding to the search for predictive markers 
of response to therapy in stage III disease. The second part focuses on identifying 
prognostic markers in stage II and III sporadic colon cancer to distinguish different 
subgroups of patients needing different therapies.
In chapter one the epidemiology, pathophysiology and classification of colon cancer 
are shortly presented. In chapter two, the value of two different polymorphisms in 
the thymidylate synthase gene as predictive markers of response to 5-FU in stage III 
sporadic colon cancer patients is studied. Chapters 3 and 4 deal with the value as 
predictive markers of SNPs in genes coding for enzymes involved in the metabolism of 
5-FU and oxaliplatin and DNA damage repair in stage III colon carcinoma patients. In 
chapters 5 and 6 the role of mutations in genes involved in known signalling pathways 
as prognostic markers is described. In chapter 7 the “allelic state” of the TP53 tumor 
suppressor gene in colon cancer and its role in disease prognosis are discussed. 
Chapter 8 focuses on genomic aberrations linked to the BRAF V600E mutation. Chapter 
9 gives an overview of the technical issues of KRAS mutation detection assays before 
implementation in daily diagnostic practice. Finally, concluding remarks and future 






1. Epidemiology of sporadic colon cancer
Colorectal cancer is one of the most frequent malignancies in the Western world. In 
the Netherlands the incidence of colorectal cancer reaches 10 000 new cases per year 
with a mortality of 3000 to 4000 patients every year1,2. Exclusion of rectal tumors 
leaves an incidence of 7000-8000 new colon cancer cases each year. Worldwide, 
approximately 1,2 million people developed colorectal cancer in 2008 and the disease 
related mortality was about 36%3,4. As more patients survive longer, the prevalence of 
colon cancer is increasing.
The disease affects slightly more men than women and sporadic colon cancer is 
considered to be a disease of the elderly with a median age at diagnosis of 70 years1. 
Several environmental and life style factors are suspected to increase colon cancer risk 
such as lack of physical activity, the consumption of red meat, cigarettes and alcohol. 
Other factors like intake of vegetables and fruit, a fibre rich diet or aspirin intake are 
considered possible protective factors for colorectal cancer5,6.
Colon cancer can be subdivided in hereditary or sporadic depending on the presence 
or absence of familial genetic predisposition for the development of this type of cancer. 
Around 10-30% of the diagnosed colorectal cancers are considered to be hereditary, 
including cases of Familial Adenomatous Polyposis (FAP), Lynch syndrome previously 
known as HNPCC (Hereditary Non Polyposis Colorectal Cancer), MUTYH Associated 
Polyposis (MAP) and others7. The majority of the colon cancer cases are considered to 






Colon adenocarcinoma emerges from normal colonic epithelium as a result of a 
sequence of genetic mutations and genomic alterations that lead to uncontrolled 
cell division and tumor formation. Such a sequence of events was first postulated by 
Vogelstein in the so-called Vogelgram, in which genetic alterations were schematically 
placed in the different morphologically recognisable phases of tumorigenesis. Grossly, 
there are two recognisable forms of sporadic colonic genetic instability; chromosomal 
instability (CIN) and the serrated form characterized by microsatellite instability 
(MIN)3,8,9. CIN and MIN were defined based on the insights from studies on FAP and 
Lynch syndrome respectively.
a. Chromosomal instability
The CIN pathway characterizes the majority of colon cancer tumors, around 80% of 
sporadic colon tumors develop through this pathway. The earliest identifiable lesion is 
the so called aberrant crypt focus (ACF)10,11. Certain mutations are already found in ACF 
like mutations in the KRAS and APC genes. Eventually, the dysplastic crypts will evolve 
into an adenomatous polyp10. Adenomatous polyps are benign but they can degenerate 
into malignant lesions.  Although, polyps are frequently found in the large bowel of 
healthy individuals older than 50 years, only a relatively small fraction of polyps evolve 
into a malignant adenocarcinoma. Adenocarcinomas invade beyond the muscularis 




mucosae and can spread to regional lymph nodes and systemically. The transition from 
normal epithelium to benign adenoma and finally to malignant carcinoma is a relatively 
slow process that, in case of sporadic cancer can take several years. In the case of 
FAP, patients already develop thousands of adenomatous polyps by late adolescence. 
These FAP patients carry a germ line mutation in the APC gene; according to Knudson’s 
hypothesis, in FAP only a second hit is needed to lose APC function12. During malignant 
transformation, the cells will get a growth advantage and start to divide uncontrollably 
through the sequential acquisition of several mutations in pivotal signal transduction 
pathways (KRAS, TP53). Genomic aberrations such as 17p and 18q deletions lead to 
genetic instability as shown in figure 113 14. This model proposed by Vogelstein is still 
a valid model of colorectal carcinogenesis although several adaptations have been 
envisaged15,16. 
CIN tumors are characterized by numerical and structural chromosomal aberrations. 
CIN is probably caused by alterations in a myriad of systems like mitotic spindle 
checkpoints, centrosome regulation systems, DNA damage checkpoint genes, cell cycle 
regulators, telomeres and telomerases11,17. The majority of CIN tumors are aneuploid 
with highly aberrant DNA indexes in contrast to those tumors that are near diploid or 
pseudodiploid. The latter however, do show as well structural chromosomal aberrations 
although not numerical18. The prognostic value of ploidy in clinical practice has been a 
matter of discussion. However, recently it was established that DNA ploidy and CIN are 
prognostic markers19-21. Frequently, CIN is accompanied by mutations in known tumor 
suppressor genes like TP53 (40-50%), SMAD4 (10-20%) and oncogenes such as KRAS 
(30-50%) or PIK3CA (~20%) 17.
b. Microsatellite Instability/ Serrated lesions 
The identification of the Lynch syndrome evidenced that a different form of 
tumorigenesis could lead to colon cancer. The Lynch syndrome is the most common 
form of hereditary colon cancer. Patients with this syndrome have a very high risk 
of colon cancer and an increased risk of developing other tumors like endometrial 
or ovarian cancer. The adenoma carcinoma sequence differs at the genetic and 
histopathological level; Lynch syndrome tumors are driven through germ line mutations 
in care taker genes in contrast to the gatekeeper function that tumor suppressor genes 
such as APC hold22. In Lynch syndrome, germline mutation and secondary inactivation 





the incapacity of repairing specific DNA damage caused by the slippage of the DNA Taq 
polymerase. As a result, especially repetitive sequences, the so called microsatellites, 
become shorter or longer in tumor cells as compared to normal cells. Generally, these 
microsatellites are located outside coding regions, however, mistakes in microsatellites 
present in gene coding regions can be affected as well leading to the inactivation of 
certain genes like Tumor Growth Factor β receptor2 (TGFβR2)  and Insulin growth 
factor like 2 receptor (IGF2R)11. A Lynch syndrome lesion has its sporadic counterpart in 
tumors with microsatellite instability, the so-called MSI-high or MSI-H tumors, mostly 
without gross chromosomal instability. MSI is seen in 15 to 20% of sporadic colon 
cancer cases and it is also caused by the inactivation of the MMR system. The latter 
occurs through hypermethylation of the promoter sequence of the hMLH1 gene and 
not through mutation23,24. Phenotypically and clinically, MSI-H tumors are frequently 
right-sided tumors, poorly differentiated, with mucinous histology, with extensive 
intraepithelial lymphocytic infiltration and in general with a better outcome than other 
types of tumors25,26. The precursor lesion in this sequence to sporadic MSI-H tumor 
is the so called, sessile serrated polyp. An early mutation typical of this pathway is 
the BRAF V600E mutation which is subsequently followed by hypermethylation of 
the promoter region of the hMLH1 gene accompanied with MIN and resistance to 
apoptosis27,28. Furthermore, the MSI-H tumors show extensive methylation of other 
genes like HPP1, Era, MyoD1, RUNX3, CDKN2A and the Methylated in tumor (MINT) 
sequences29 annotated as the CpG Island Methylator Phenotype (CIMP). In order to 
study CIMP tumors in a standardized manner, an internationally well defined panel of 
markers is needed; however, the best gene panel to classify this subtype of tumor is still 
a matter of discussion30-34. 
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3. Signal transduction pathways in colon cancer pathogenesis
Many cellular signaling pathways become deregulated in tumors through mutational 
activation or inactivation of the genes/proteins implicated in such pathways. Signaling 
pathways are complicated networks of proteins with much interaction as shown in 
figure 2. Certain pathways are preferentially disrupted in colon cancer, making the 
proteins involved, drugable targets for new therapies.
  
a. Wnt/β-catenin signaling pathway
The Wnt signaling pathway plays an essential role in the development and maintenance 
of intestinal epithelium. Deregulation of this pathway is observed in many cancer 
types and particularly in colon cancer. Briefly summarized, the pathway acts as 
follows; upon Wnt activation, β-catenin translocates to the nucleus where it acts as 
a transcription factor for several target genes like c-myc and cyclin D1. If Wnt is not 
activated, β-catenin is targeted for degradation via a complex formed among others by 
Adenomatous Polyposis Coli (APC) and Glycogen Synthase Kinase 3β (GSK3β). The APC 
gene is frequently mutated in colorectal cancers. Mutations give rise to a truncated 
protein leading to a decreased degradation of β-catenin, its accumulation in the 




The Epidermal Growth Factor receptor (EGFR) signaling pathway is essential for 
epithelial cell growth. EGFR is a tyrosine kinase that signals downstream via KRAS and 
BRAF to the MAP kinases finally to the nucleus where it stimulates cell division and 
proliferation37. EGFR can also signal through the Phosphatidyl Inositol 3 kinases (PI3K) 
pathway with the AKT kinase and finally mTOR as downstream targets.
The whole pathway is altered in more than 50% of all colon cancer cases38. Moreover, 
it is an important target for cancer therapy; monoclonal antibodies blocking EGFR 
activity currently form part of the targeted therapy in metastatic colon cancer. 






c. p53 cell cycle checkpoint pathway and apoptosis pathway
Although, p53 is not involved in a signal transduction pathway, it plays an important role 
in colon carcinogenesis as over 50% of colon tumors inactivate p53. This inactivation is 
considered to be a late event in the adenoma carcinoma sequence and correlates with 
chromosomal instability.  
p53 is a transcription factor with key roles in essential pathways for normal cellular 
physiology. It is implicated in DNA damage repair, apoptosis, senescence, cell cycle 
checkpoints, cell proliferation and cytoskeletal characteristics46. 
Of importance for colon carcinogenesis is p53 function of sensing DNA damage and 
causing cell cycle arrest at G2 phase. When p53 is activated it will transcribe many 
downstream targets like CDKN1A and GADD45 which inhibit cyclin dependent kinases 
causing subsequently cell cycle arrest. Furthermore, when DNA damage is not 
repairable, p53 will direct the cell to apoptosis by activating BAX. TP53 is located on 
chr17p and is one of the genes very frequently inactivated in human cancers leading to 
resistance to apoptosis and accumulation of DNA and genomic aberrations47,48. 
  
d. TGFβ/ BMP pathway
The Transforming Growth Factor β (TGFβ) superfamily consists of the TGFβ and Bone 
Morphogenetic Protein (BMP) subfamilies. TGFβ is involved is several cellular processes 
like proliferation, differentiation, migration and apoptosis. It seems that TGFβ has a 
dual role stimulating both cell growth and growth arrest depending on the targets it 
activates. Its role in carcinogenesis is therefore complex acting as both tumor suppressor 
gene and oncogene49. The tumor suppressor activity is driven through Smad signaling. 
Upon ligand binding to the TGFβ receptor, intermediate factors like Smad2 and Smad3 
will become phosphorylated and will form a complex with Smad4 which will in turn 
translocate to the nucleus and inhibit c-myc transcription and activate cyclin associated 
proteins like cyclin D1 and p21. Other members of the Smad family like Smad6 and 
Smad7 act as “inhibitors” of the TGFβ signaling by interfering with the activation of 
the effector Smads. Smad7 is activated by TGFβ itself representing a negative feedback 
loop for the pathway regulation. Contrasting with this growth suppressive function, 
TGFβ can enhance invasion capacity of tumor cells and facilitate metastasis, considered 
to be oncogenic events. The switch between tumor suppression effects and tumor 
progression effects is quite complex and partly due to the decreased signaling through 
TGFβR2 and Smad molecules also favoring MAPK signaling49. In colon cancer, TGFβR2 is 
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found mutated in up to 80% of MSI-H tumors and 15% of MSS tumors35 50.
As TGFβ, BMPs also signal through Smad proteins and act as a tumor suppressor 
gene in colon carcinogenesis. Once a BMP ligand is bound to the BMP receptors, 
these will become phosporylated and in turn will phosphorylate Smad1, Smad5 and 
Smad8 which will associate with Smad4 and enter the nucleus where they regulate 
gene transcription51. BMP2 seems to act in colonic epithelium as a tumor suppressor 
promoting apoptosis of epithelial cells52. BMPs are involved in colon carcinogenesis 
as suggested by the mutations in BMP receptor type Ia (BMPR1A) in the pathogenesis 
of juvenile polyposis53. Moreover, in sporadic colon cancer, the BMP pathway is 
inactivated in 70% of the cases through loss of Smad 4 or loss of BMPR2 expression. 
In sporadic colon cancer, the BMP signaling seems to have a role in tumor progression 







Figure 2: Signaling pathways in colon cancer pictures from cell signaling technology 
(www.cellsignal.com viewed Feb 14, 2011) a) Wnt/β-catenin pathway b) EGFR/KRAS/
BRAF/MAPK and PI3K pathways (adapted from Allison54) c)p53 cell cycle checkpoint 
pathway (www.cellsignal.com viewed Feb 14 2011) d) TGFβ/BMP pathway (www.





4. Current classification and therapy of sporadic colon cancer
Clinicopathologically, colon cancer is classified in different stages according to a 
stepwise analysis of items such as the extent of colonic wall infiltration, the absence or 
presence of lymph node metastasis and the existence of distant metastasis. Nowadays, 
other factors are also being taken into account like venous, lymphatic or perineural 
infiltration, tumor budding, proportion of stroma and tumor grading, as these 
parameters have shown to influence prognosis as well 6,55-57. In daily clinical practice, 
the TNM classification of the American Joint Committee on Cancer (AJCC) and the 
“Union Internationale Contre le Cancer” (UICC) is used (Table 1). 
At diagnosis 14% of the patients have stage I disease, 28% stage II, 37% stage III and 
21% stage IV. Prognosis is frequently measured as five-year survival. Five-year survival 
is stage dependent and varies from over 90% in stage I to less than 5% in stage IV 
disease 3,58. 
The treatment of colon cancer depends mainly on disease stage at diagnosis. Patients 
with stage I and II have localized disease and are therefore considered cured after 
surgery whereas patients with stage III disease will receive adjuvant chemotherapy as 
the disease has spread outside the bowel into the lymphatic system. In general, stage 
IV patients are considered not curable because of the spread of the disease to different 
organs and tissues. These patients will therefore receive palliative treatment. 
Stages II and III form the focus of this thesis as the disease at these stages is potentially 
curable. Much benefit can be obtained from a molecular subclassification leading to a 
more patient tailored therapy. 
In Europe, adjuvant chemotherapy for stage III consists on 5-fluorouracil (5-FU) or 
its derivate capecitabine in combination with oxaliplatin during six months; the so 
called FOLFOX (5-FU and oxaliplatin) or CAPOX (XELOX) (capecitabine and oxaliplatin) 
regimes6. The use of adjuvant chemotherapy in stage III is nowadays widely accepted 
as it has been shown to reduce cancer related death in 29% as 5-FU monotherapy and 
even further as combination therapy with oxaliplatin 1,59-62.  
The value of adjuvant chemotherapy in stage II remains however more 
controversial58,63,64. Although several international trials have failed to show any benefits 
of this treatment in stage II patients, the recurrence rate at this stage, over 15%, is 
relatively high for localized disease 58. Therefore, a new subgroup of stage II patients 





following characteristics; T4 tumors, poorly differentiation, less than 10 lymph nodes 
yield in the surgical resection specimen (in the Netherlands) or a clinical presentation 
with bowel obstruction or perforation. Patients classified as high risk stage II receive 
the same adjuvant chemotherapy scheme as stage III patients do. 
T primary tumor
T1 tumor invades submucosa
T2 tumor invades muscularis propria
T3 tumor growths through muscularis propria into 
subserosa
T4a tumor penetrates visceral peritoneum 























N regional lymph nodes
N0 no regional lymph nodes affected
N1 one to three regional lymph nodes affected
N2 more than three lymph nodes affected
M distant metastasis
M0 no distant metastasis present
M1 distant metastasis present
Table 1: AJCC/UICC classification of colon carcinoma 3.
Targeted therapies have made their entrance in colon cancer treatment but their 
use remains limited to metastatic colon cancer stages. Compounds like bevacizumab 
targeting Vascular Endothelial Growth Factor (VEGF), the mouse anti human monoclonal 
antibody cetuximab or the humanized antibody panitumumab both targeting EGFR 
have shown survival benefit in stage IV patients with no mutations in downstream 
effector molecules 40,65,66.  The benefit of these therapies in earlier stages of the disease 
is currently being studied. The preliminary results of the NSABP-Protocol 08 clinical 
trial comparing FOLFOX alone or in combination with bevacizumab in the adjuvant 
setting show, however, no survival improvement in stage II and III colon cancer patients 
and therefore the administration of bevacizumab as adjuvant therapy is not advised at 
this point 67-69.
In conclusion, there is need for a more accurate classification of patients who are likely 
to benefit from adjuvant chemotherapy and patients who are not. This classification 
could be based not only on clinicopathological features but also on molecular profiles 
22
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of the tumors. These molecular markers, responsible for different phenotypes and 
clinical behaviors, could be used in the future as determinants of outcome or markers of 
response leading to personalized therapy and management of the disease3,9,26,58,64,70,73. 
The main goal of this thesis is to find these molecular markers of prognosis or of 
response to therapy in stage II and III disease. The following paragraphs describe the 





5. Pharmacogenomics and predictive markers of therapy response
As the human genome has been completely sequenced, it has become clear that DNA 
variability is even larger than originally thought. Single nucleotide polymorphisms 
(SNPs) or, in other words variation in one base pair, constitute the most frequent 
variation in the DNA sequence with an estimated frequency of one polymorphism 
in hundred nucleotides. Other variation types have been described as well, such as 
short tandem repeats (STRs) and copy number variations (CNVs). However, the exact 
consequences of this kind of variation in gene expression and protein function are less 
understood.
SNPs can reside in coding as well as in non coding regions, besides, SNPs can be 
non synonymous and synonymous depending on whether they cause an aminoacid 
substitution or not, respectively.  The latter can cause however, discrete alterations in 
protein function like slightly different protein folding or altered expression through the 
use of a less effective codon 74. 
SNPs are present throughout the whole genome influencing the expression of several 
proteins. Enzymes involved in drug metabolism are no exception to this genetic 
variation. Pharmacogenomics is the discipline that studies the effect of genetic 
polymorphisms in the effectiveness of certain drugs. It can be hypothesized that 
variation in genes coding for proteins involved in the metabolism of chemotherapeutic 
agents as well as in DNA repair, or genes coding for target proteins of chemotherapeutic 
drugs are potentially good candidates for predicting response of a patient to a certain 
chemotherapeutic drug, becoming a predictive marker or marker of response75-78. In 
other words a predictive marker is a patient’s pheno and genotype determining the 
patient’ s response to a certain drug.
In colon cancer, several molecules involved in the metabolism of 5-FU and oxaliplatin 
as well as the target protein of 5-FU and DNA damage repair proteins are subjects 
of pharmacogenomic investigation. For new targeted therapies, like EGFR blocking 
agents, mutations in downstream effector molecules like KRAS and BRAF are predictive 




Prognostic markers are tumor related or patient related characteristics that identify 
the tumor as aggressive or less aggressive. 
There are several possible approaches to identify new prognostic markers. One 
is to study the prognostic value of mutations in known genes involved in e.g. signal 
transduction pathways, apoptosis, cell cycle or DNA repair. Other strategies search the 
whole genome of the tumor or its expression signature to identify profiles that are 
associated with a good or poor prognosis.
a. Genetic mutations 
Certain mutations are typically found in specific types of cancer48. In the case of colon 
cancer, mutations in APC and KRAS have been extensively found 80. As previously 
mentioned, with the introduction of targeted therapies, mutations in genes such 
as KRAS and probably BRAF have become very important as predictive markers of 
response in stage IV colon carcinoma 40,43,79. However, their prognostic value in earlier 
disease stages is not clear yet80,81 and it is a subject of ongoing research. Nevertheless, 
there is some evidence towards a prognostic role in colorectal cancer for mutations 
in BRAF and PIK3CA as they have been associated with a poor prognosis in MSS colon 
tumors and in rectal cancer respectively82,83
Gene mutations might be used to classify tumors more accurately according to their 
molecular signature instead of their histopathological phenotype. Tumor heterogeneity 
can however pose a serious problem to this aim. Intratumor heterogeneity has 
been recognized previously; however, the biological and clinical implications of this 
heterogeneity are still largely unknown. However, tumor initiation and progression is 
seen, quite simply, as a linear succession of acquisition of mutations and other genetic 
hits leading to clonal expansion. Tumor cells are constantly changing and adapting 
to their microenvironment and not all tumor cells are exposed to exactly the same 
microenvironment as they receive different external signals (growth factors, oxygen, 
blood supply, inflammatory cells). Tumors therefore, are evolving in different directions 
giving rise to different clones within a single tumor with potentially different behaviours. 
Clinical cancer research is limited by the fact that patient material represents the 
tumor status at a given time, namely time of diagnosis and surgery. Therefore tumor 





tumor cell populations are not always monoclonal 86 and that several cell lines with 
different genetic abnormalities can co-exist in the same tumor 87.
Tumor heterogeneity also constitutes a technical challenge. Laser capture based 
microdissection and cell separation by flow cytometry or magnetic beads can be useful 
in obtaining homogeneous tumor cell populations. However, these are time consuming 
techniques not really feasible to study large cohorts of patients 13. 
In the context of tumor heterogeneity another problem can be seen, the way to 
interpret results clinically from very sensitive analyses that are able to detect very small 
populations of tumor cells88. The significance of 1% mutated cells in a tumor for decision 
making in targeted therapy remains unknown. Moreover, discrepancies in mutation 
patterns between primary tumors and metastatic clones have also been described 38. 
This issue can complicate the use of targeted therapies and the implementation of 
molecular marker testing for therapy decision making 89. 
b. Whole genome analysis in sporadic colon cancer
Whole genome research has been widely applied in colon cancer research. Results 
have been obtained using different platforms like gene expression arrays, comparative 
genomic hybridization (CGH), array CGH and more recently, high density SNP arrays and 
next generation sequencing. Results from expression arrays are able to discriminate 
between different disease stages, mutational phenotypes, lymph node positivity and 
prediction of disease recurrence 90-95. Recently, a prognostic signature for stage II and 
III colon cancer containing eighteen genes was published96. Clinical validation and 
regulators approval are difficult to obtain before these tests can be used in daily clinical 
practice.
Several genomic regions have been consistently identified to be altered in colon cancer 
such as losses of chromosomes 17p, 18, 4p, 8p and 14q and gains of 8q, 13q, 20, 7p, 17q, 
1q, 11, 12p and 19 13,97-104. Moreover, these genomic alterations have been associated 
to colon cancer progression 13. However, identifying the genes or regulating sequences 
implicated in these altered genomic regions has turned out to be more difficult than 
initially thought 105. 
Despite all the effort, until date, only two molecular markers are accepted as prognostic 
markers in colon cancer, namely chr.18q loss and MIN 55,106. The existence of a “genomic 
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Abstract
Although the predictive and prognostic value of thymidylate synthase (TYMS) 
expression and gene polymorphism in colon cancer has been widely studied, the 
results are inconclusive probably because of methodological differences. With this 
study, we aimed to elucidate the role of TYMS gene polymorphisms genotyping in 
therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant 
chemotherapy.
Two hundred and fifty one patients diagnosed with stage III colon carcinoma treated 
with surgery followed by 5-FU based adjuvant therapy were selected. The variable 
number of tandem repeats (VNTR) and the single nucleotide polymorphism (SNP) in 
the 5’untranslated region of the TYMS gene were genotyped. 
There was a positive association between tumor T stage and the VNTR genotypes 
(p=0.05). In both univariate and multivariate survival analysis no effects of the studied 
polymorphisms on survival were found. However, there was an association between 
both polymorphisms and age. Among patients younger than 60 years, the patients 
homozygous for 2R seemed to have a better overall survival, whereas among the 
patients older than 67 this longer survival was seen by the carriers of other genotypes.
We conclude that the TYMS VNTR and SNP do not predict response to 5-FU therapy in 
patients with stage III colon carcinoma. However, age appears to modify the effects of 






5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice in the treatment of colon 
cancer. 5-FU causes cell death through two different mechanisms 1. One mechanism 
is the incorporation of fluorouracil triphosphate (FUTP) into RNA causing disruption 
of normal RNA processes. The second mechanism of action consists on inhibition of 
thymidylate synthase (TS). TS provides the sole de novo source of thymidylate for 
DNA synthesis, thus TS inhibition causes depletion of nucleotides disrupting DNA 
synthesis and repair. Besides, it also causes DNA damage through misincorporation 
of deoxyuracil triphosphate (dUTP) into the DNA strand 1. The fact that enhanced TS 
protein expression has been described as a mechanism of acquired 5-FU resistance 2 
supports the thesis that TS inhibition is the main mechanism of action of 5-FU. 
Because of its role as potential main target of 5-FU, TS has been widely studied as a 
molecular maker of therapy response in colorectal cancer, without conclusive results. 
Several studies have focussed on quantitation of TS protein by immunohistochemistry 
(IHC) 3-12 or mRNA expression 8,13-22 in tumors and metastasis whereas others have 
focussed on gene polymorphisms genotyping 6,11,23-39. Besides technical differences, 
heterogeneity in patient selection also plays a role in the lack of consistency between 
results. Many studies for instance have included patients with rectal cancer 26,32,33,38, 
while these are treated differently than colon cancer. Furthermore some reports 
described heterogeneous cohorts of patients including all disease stages and patients 
who did not receive 5-FU based adjuvant therapy at all 24,26,32,37,38. Results are therefore 
frequently contradictory 40. 
We have recently reported the reliability of different methods for TYMS typing, like 
genotyping of three known gene polymorphisms (see figure 1), TS protein expression 
quantitation, TYMS gene amplification and loss of heterozygosity in predicting 5-FU 
therapy response 41. From these results, it seemed that genotyping of the 5’untraslated 
region polymorphism of the TYMS gene was more reliable for predicting response to 
therapy than protein expression, as determined by IHC and than genotyping the rest of 
polymorphisms in the 3’UTR. 
The aim of this study was to determine the value of the TYMS gene 5’UTR polymorphisms 
as a possible molecular marker for 5-FU response in a well defined, homogeneous 
population of stage III colon cancer patients who had been treated with 5-FU based 
adjuvant chemotherapy.
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Figure 1: Schematic representation of the TYMS gene with known polymorphisms in 
5’ untranslated region (5’UTR) and 3’ UTR. On the 5’UTR the 28 bp repeat with the 
SNP in the third repeat. Two or three repeats are the most frequent alleles in the 







All patients (n=251) were stage III colon carcinoma patients treated with surgery 
followed by 5-FU based adjuvant chemotherapy between 1995 and 2004 in four 
different hospitals in the Eindhoven area in the south of the Netherlands. 
Two hundred forty two patients (96.4%) received 5-FU in combination with leucovorin 
following the Mayo regime, 4 patients (1.6%) had 5-FU plus levamisole and finally 5 
patients (2%) received capecitabine.
Routine histopathological diagnoses were performed in a central laboratory, the PAMM 
laboratory for Pathology in Eindhoven. Epidemiological data and tumor characteristics 
of all patients included were extracted from the Eindhoven Cancer Registry of the 
Comprehensive Cancer Centre South (IKZ, the Netherlands). Follow up information 
was obtained from the medical records of these patients. The research protocol was 
approved by the Scientific Committee of the Catharina Hospital Eindhoven.
Methods
VNTR typing
DNA was obtained after proteinase K digestion of 5 sections of 5 µm from formalin fixed 
paraffin embedded (FFPE) blocks with normal colonic tissue. Subsequently, the tissue 
digest was purified with HPPTP purification kit for genomic DNA (Roche diagnostics, 
Almere, the Netherlands). PCR for the VNTR was performed using the following primers: 
(forward) 5’gcg gaa ggg gtc ctg cca3’ and (reverse) 5’tcc gag ccg gcc aca ggc at3’. The 
reaction was performed in 50µL final volume as described elsewhere42. PCR products 
were separated by electrophoresis on a 2% agarose gel. The expected product sizes 
were 107 bp for the 2R allele and 135 bp for the 3R allele.
SNP genotyping
Subsequently, the previously obtained PCR products were digested by HaeIII restriction 
enzyme during one hour at 37°C (New England Biolabs, Ipswich, United Kingdom). The 
G to C base change removes a HaeIII restriction site present at position 12 of the second 
28 bp repeat of the 3R allele. PCR products of carriers of the G allele will be digested 
giving an additional shorter band of 66 bp after gel electrophoresis on a 3% agarose gel.
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Statistical analysis
Statistical analyses were performed using SPSS software package for Windows
(Chicago, Il., U.S.A.). Categorical data were analyzed by means of a chi-square or 
Fischer’s exact test. To study the difference in median age between the different VNTR 
and SNP genotype groups, age was used as a continuous variable to perform a Kruskal-
Wallis test. After this, age at diagnosis was categorized according to tertiles for further 
analyses.
To study the effects of the different polymorphisms on 5-FU response, survival analysis 
was used. The univariate survival analysis was performed using the Kaplan Meier test. 
Differences between survival curves were tested for significance by the Log-rank test. 
Overall survival (OS) was the time between surgery and death discriminating between 
death because of colon cancer or because of other reasons when this was specified 
in the medical records. Disease free survival (DFS) was the time between surgery and 
disease progression. Cancer specific survival (CSS) was defined as the time between 
surgery and death because of colon cancer. Cox proportional hazards regression 
analysis was used for multivariate survival analyses. All tests were two-tailed and 







Patient and tumor histopathological characteristics are shown in table 1. All patients 
had positive lymph nodes and no recognizable distant metastasis at time of diagnosis. 
10 patients (4 %) developed distant metastasis within the first four months following 
surgery. 
Median follow-up was 47 months (range 2-133 months). 122 patients (49%) were still 
alive at the end of the follow up period, 30 patients (12%) were alive but had had disease 
progression, 80 (32%) died due to cancer related causes and 17 patients (7%) died due 
to non cancer related causes according to the medical records. Finally, medical records 
of two patients were incomplete and their follow-up status was unknown.
VNTR distribution
VNTR distribution and association with studied variables is shown in table 1. Distribution 
of the VNTR in the population studied followed Hardy Weinberg equilibrium. There was 
a significant association between tumor T stage and VNTR alleles. Patients homozygous 
for the 2R allele had significantly more frequently low T stages than did heterozygous 
and homozygous 3R (p=0.05).
There was, further, a significant association between age at diagnosis and the three 
genotypes. Median age in the group with the 3R/3R genotype was significantly 
lower than median age in the 2R/2R and in the 2R/3R group; 61 years vs. 64 and 65 
respectively (H=14.633 p=0.001 99%CI 0.000-0.001). To further study the association 
between age at diagnosis and genotypes and their role in survival, we categorize age 
in three different groups according to tertiles. These tertile groups corresponded in 
our study population to the following age categories; younger than 60 years, between 
60-67 years, and older than 67 years, respectively. There was a significant relationship 
between the three genotypes and the three age categories (p=0.02).
SNP distribution
Two hundred and thirteen out of 251 patients had enough PCR product available to 
study the G>C SNP present in the second repeat of the 3R allele.
Frequencies of the different SNP alleles in our patient population were in agreement 
with the in the literature published frequencies and are shown in table 2. There was 
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no significant association between the different SNP alleles and any of the categorical 
variables tested. 
Age was tested as a continuous variable and there was a significant association with the 
SNP genotypes (H=15.135 p=0.01 99%CI 0.006-0.01). Median age in the 3G/3C group 
was 53,5 years, whereas all the other genotype groups had a median age greater than 
60 years (figure 2). When age was categorized according to tertiles, a positive trend was 
seen towards an association between age tertiles and the SNP (p=0.06).
Categorization into high and low TS expression
Based on the effects of the VNTR in TS protein expression as described in the literature, 
our patient population was divided in two putative categories low and high TS 
expression, according to the genotypes found: homozygous 2R and carriers of the 3R 
allele (3R/3R, 2R/3R), respectively 30,31,34,42,43.
When additionally the SNP genotypes were included, patients could be divided in the 
following groups: putative high TS expression as carriers of the G allele (3RG/3RG, 
3RG/3RC, 2R/3RG) and putative low TS expression as carriers of the C allele plus the 
Figure 2: Age distribution according to SNP genotypes (Kruskal-Wallis H=15.135 
p=0.01 99%CI 0.006-0.0.
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2R homozygous (2R/2R, 2R/3RC, 3RC/3RC). 60% of the patients were categorized as 
putative low expression vs. 40% putative high expression.
Survival analysis
Analysis of the total population revealed no associations between the genotypes, 
either independently or in categories (as low and high expression), and overall survival, 
disease free survival or cancer specific survival (figure 3a and 3b). These results were 
confirmed by a multivariable Cox proportional hazard model including the following 
variables; T stage, N stage, differentiation grade, sex, tumor location and TS SNP 
category or VNTR category.
Mean time to progression in the groups according to SNP and VNTR category did not 
differ significantly (SNP category low 42 months and high 44 months. VNTR category 
low 42 months and high 42 months).
Since there was an association between TYMS gene polymorphisms and age, we 
stratified to age tertiles to study the effect of the polymorphism on survival in relation 
to age. As shown in figure 4, there was a difference between old and young patients. 
Moreover, this difference could be seen when we classified the patients as putative low 
and putative high TS expression according to the SNP (figure 4a) and to the VNTR alone 
(figure 4b). There was a switch in the genotype associated to a longer overall survival 
as the patients age increased. In other words, among patients younger than 60 years, 
the 2R homozygous had a better overall survival (p=0.02) whereas between patients 
older than 67 years, the ones with putative high TS expression (G allele) had a longer 
overall survival (p=0.06). These age dependent relations were also seen for CSS albeit 
not significant. However, there was no age dependent effect for DFS.
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Figure 3: Kaplan Meier plots for OS, DFS, and CSS according to:
a) SNP categories TS low (2R homozygous plus C allele) and high (G allele) producers 














Figure 4: Kaplan Meier curves of the effects on overall survival of the VNTR and SNP 
categories stratified to age tertiles. a) SNP category b) VNTR category.
52
 TYMS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer 
patients 
Discussion
Although, several studies have been published about the value of TS in colorectal 
cancers, as reviewed by Popat 40, the results are often contradictory and inconclusive 
particularly in patients treated adjuvantly. 
Therefore this study aimed to elucidate the value of TYMS gene polymorphisms as 
possible molecular marker of therapy response in stage III colon carcinoma patients 
treated with adjuvant 5-FU chemotherapy. 
In our well defined population of stage III colon cancer patients, TYMS genotype 
as determined by the SNP and the VNTR on the 5’UTR of the gene had no effect on 
patient outcome. There were no differences in survival (OS, DFS, CSS) between patients 
according to the genotypes independently or categorized as high en low TS expression 
based on either the TYMS SNP or on the VNTR alone (figure 3a and 3b). Although, in 
a previous publication we reported a predictive value for the TYMS VNTR 41, only a 
small number of patients were studied at that time and the apparently contradictory 
results could be explained by the difference in patient numbers between studies. In the 
present larger cohort of patients, we were not able to reproduce our previous results. 
Moreover, inconsistent results over the predictive value of TYMS genotype and 
phenotype are a common feature in the literature. To our knowledge, there are at 
least, seven reports studying the value of both 5’UTR polymorphisms, VNTR and SNP, 
in colorectal carcinoma 6,31-33,35,44,45. Our study agrees with Lecomte et al, Ruzzo et al 
and Prall et al; partly with Fernandez Contreras et al and argues with Kawakami et al, 
Marcuello et al and Lurje et al. In contrast with our patient population which consisted 
in stage III colon carcinoma patients only, all the previous publications included rectal 
carcinomas and studied either advanced colorectal cancer 33,35 or combined different 
disease stages 6,32,45. We excluded rectal cancer patients because their treatment differs 
greatly from that of colon cancer patients. Rectal and colon cancer are likely to be 
two different diseases arising from different pathogenetic pathways and with different 
clinical behaviours 46. We, as Prall et al included only stage III patients in order to have 
a homogeneous population. Accordingly, similar results were found although Prall and 
co workers included rectal cancer patients, albeit not neoadjuvantly treated and their 
patients’ population was smaller 44. 
Several authors have described a functional role of the TYMS 5’UTR polymorphisms 





level than homozygous 2R/2R or C allele carriers 30,31,34,42,43. A higher TS expression has 
been described as a mechanism of 5-FU resistance2, hence one would expect that 
carriers of the 3R allele and of the G allele would respond worse to 5-FU and have 
a poorer survival. Our results do not support this thesis. However, the regulation of 
TS expression and function remains quite complex and most likely is influenced by 
many still unknown factors 2,47. Thus, ideally to explain the biological role of TS in 
the resistance to 5-FU, other techniques to objectively study protein expression and 
preferably function, would probably be more accurate. Therefore, our results based 
on DNA genotyping should not be interpreted as a biological explanation of 5-FU 
resistance mechanisms but as an answer to whether genotyping is a good marker for 
therapy response in colon cancer patients.
Interestingly, in our population, age seems to play a role on the TYMS genotype 
distribution and appears to modify the effects of the genotypes on survival. Indeed, 
the allelic distribution of both polymorphisms varied depending on age: the median 
age of the 3RC/3RG genotype was significantly lower in comparison to other genotypes. 
Similar results have been already reported by Odin et al. The authors described an 
inverse correlation between TYMS gene expression and age in colon cancer patients 48. 
This relationship could point to a role of the TYMS gene polymorphisms in colon cancer 
risk. Hubner et al described a decreased risk of colon carcinoma between homozygotes 
for the TYMS 1491del6 on the 3’UTR of the gene. However, these authors did not find 
any role for the polymorphisms on the 5’ UTR 49. Further research is needed to study 
the allelic distribution in the normal population and to see whether this link remains 
significant. 
Furthermore, the effect of the TYMS genotypes on overall survival was also modified 
by age. There was a switch in the TYMS genotypes associated to longer overall survival 
as age increased. In other words, genotypes associated with low TS expression 
(homozygous 2R and the carriers of the C allele) had a significant positive effect on 
survival among patients in the first age tertile category (corresponding to patients 
younger than sixty years). Conversely, these genotypes had a negative effect on survival 
among patients in the third age tertile category (i.e. older than sixty seven years). In 
the literature, an inverse association between TYMS gene expression, and age in colon 
cancer patients was already described by Odin et al, but the authors did not report its 
impact on survival.
To elucidate the underlying reasons of this age-dependent relation exceeds the scope 
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of this paper and needs additional research. Nevertheless, there is increasing evidence
that age affects normal colonic mucosa and tumors. For instance, DNA methylation has 
been shown to increase with age in normal colonic mucosa 50,51 and different protein 
expression patterns have been found in the colonic mucosa of the elderly compared to 
that of younger people 52. Moreover, Morris et al have also shown that the molecular 
aberrations in tumors differ according to age 53. Thus, our finding supports the 
hypothesis that age probably modifies the effects of different molecular pathways on 
oncogenesis and on cancer progression.
In conclusion, the TYMS polymorphisms in the 5’UTR are not good markers of 5-FU 
therapy response in this population of stage III colon carcinoma patients. However, 
further research is necessary to study the role of age as an effect modifier of the 
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Abstract
The role of pharmacogenetics in chemotherapy response in colon carcinoma is 
controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism 
as biomarkers of chemotherapy response in stage III colon carcinoma patients.
DNA was isolated from normal colonic tissue of 60 stage III colon carcinoma patients 
treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated 
SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. 
Real time PCR, sequencing and RFLP were used for genotyping.
None of the studied genotypes was associated with any of the tumor or patient 
characteristics. Moreover, none of the genotypes studied had effect on patient survival.
In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our 






In colon cancer, the role of pharmacogenetics for drug toxicity and efficacy is still under 
discussion1. 
5-Fluorouracil (5-FU) is the main drug of choice in the treatment of stage III colon 
carcinoma. Several proteins are involved in the metabolism of 5-FU and many of the 
genes coding for these proteins have been shown to be polymorphic.
Ororate phosphorybosil transferase (OPRT) and thymidine phosphorylase (TP) activate 
5-FU by phosphorylation into active metabolites which respectively incorporate into 
RNA or inhibit thymidylate synthase (TS). Dihydropyrimidine dehydrogenase (DPD) 
inactivates 5-FU in the liver 2,3. The genes encoding for these proteins harbor functional 
polymorphisms. 
The OPRT gene contains several polymorphisms, among those the G638C SNP that 
causes a glycine by alanine substitution at position 213 of the protein, which has been 
associated with a higher expression and activity of the protein and with an increased 
toxicity of 5-FU therapy 4. 
There are several polymorphisms described in the TP gene (TYMP), however there 
are no confirmed polymorphisms in coding regions causing changes in aminoacid 
sequence. The value of these polymorphisms as markers of response to 5-FU therapy 
is to our knowledge, unknown.
The polymorphisms in the enhancer region of the TS gene (TYMS) have been widely 
studied in their relation to response to 5-FU therapy and with protein expression and 
activity. The studied polymorphisms consist in a 28bp repeat at the 5’ untranslated 
region of the gene and a G>C SNP in the second repeat of the three repeat allele. In 
the Caucasian population the variants with two (2R) or three (3R) repeats are the most 
frequent alleles found. On the basis of the effects of the SNP in the second repeat of 
the 3R allele on TS protein expression, patients could be classified as high TS protein 
producers when carrying the G allele and low TS protein producers when carrying the C 
allele 5,6. However, up to date, the results concerning the effect of these polymorphisms 
in 5-FU response remain inconclusive 7. 
Finally, the DPYD gene has been shown to play a very important role in toxicity of 5-FU. 
The polymorphism in the exon/intron boundary at exon 14 is responsible for severe 
toxicity in these patients 8. However, little is known about the value of these and other 
polymorphisms as markers of response. 
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We aimed to study the value of known polymorphisms in the OPRT, TYMP, TYMS and 
DPYD genes as markers of response in stage III colon carcinoma patients treated with 








Sixty stage III colon carcinoma patients treated with surgery and 5-FU chemotherapy 
following the Mayo regime were studied. 
All diagnoses were made at a central laboratory for pathology between 2003 and 2004. 
Population data were obtained from the cancer registry database of the Comprehensive 
Cancer Centre South. Follow-up information was obtained from medical records.
The use of clinical material for this retrospective study was approved by the institutional 
review board according to the guidelines of the Dutch Federation of Research 
Associations. 
DNA was isolated from normal colonic mucosa from formalin fixed paraffin embedded 
(FFPE) material after proteinase K digestion and purification using the HPTTP kit (Roche, 
Almere, the Netherlands).
Target genes and polymorphisms
Polymorphisms must be non synonymous and confirmed by independent research 
groups. However, in the case of the TYMP gene, there were no confirmed non 
synonymous polymorphisms and therefore we chose one confirmed synonymous 
polymorphism.
OPRT
The G638C SNP (rs1801019) causing a Gly213Ala substitution was tested by real 
time PCR with the following primers and probes forward 5’ GCT GAG ACA GTT 
GGG AGA GTG A 3’, reverse 5’ TGA GTT CTT TGG GTG CTT CCT T 3’, probe for 
G allele 6FAM 5’CGA ATC ATA ATG GTT C3’and probe for C allele 6FAM 5’AGC 
GAA TCA TAA TGC TT3’. Reactions were performed using Roche chemistry in 
a final volume of 20 µl in the light cycler v2 (Roche, Almere, the Netherlands). 
TYMP
The rs470119 SNP was assessed by restriction fragment length polymorphism (RFLP). 
PCR was performed using the following primers forward 6FAM-5’TCC AGA GCC CAG 
GTA3’ and reverse 5’CTG GCC AGG GTC TCC ATC A3’. The 71 bp long PCR product was 
then digested with MboI restriction enzyme (New England Biolabs, Ipswich, United 
66
Value of gene polymorphisms as markers of 5-FU therapy response in 
stage III colon carcinoma
Kingdom). After digestion, fragment length analysis was carried out by capillary 
electrophoresis. The following fragment length was expected for homozygous GG, 
40bp and 30bp, for AA 71 bp and for heterozygous AG 71bp, 40bp and 30bp.
TYMS
The two polymorphisms in the enhancer region of this gene were typed using PCR 
and RFLP as described elsewhere 9. Briefly, the 28 bp repeat was typed by PCR means 
followed by electrophoresis on 2% agarose gel. The G>C SNP was typed by digestion of 
the PCR product with HaeIII restriction enzyme. The G to C substitution abrogates the 
restriction site for this enzyme. Subsequently, products were separated by agarose gel 
electrophoresis.  
DYPD
The SNP A1627G (rs1801159) causing the substitution of isoleucine by valine at position 
543 of the protein was tested by PCR followed by sequencing using the following 
primers, forward 5’GCA GTC ACA ATA TGG AGC3’ and reverse 5’TTA CCT TAT CAA 
GAG AGA AAG TT3’. The expected length of the product was 225 bp. Subsequently, 
PCR products were purified using enzymatic purification with ExoSapIT (USB, USA) 
and the sequencing reaction was performed using the same primers as for the PCR 
reaction and Big Dye chemistry (Applied Biosystems, Nieuwerkerk aan den Ijssel, the 
Netherlands). Sequences were analyzed using the sequencing analysis 5.3.3 software 
(Applied Biosystems)
Statistical Analysis
SPSS v.16 software package for Windows (Chicago, Il., U.S.A.) was used for 
statistical analysis. Categorical data were analyzed by means of a chi-square or 
Fischer’s exact test. The end point of this study was progression free survival (PFS 
defined as time between surgery and disease progression). Univariate survival 
analysis was performed by Kaplan Meier analysis and differences were analyzed using 
the Log Rank method. Hazard Ratios and multivariate analysis were calculated using 
the Cox Proportional Hazard model. 






Briefly, characteristics of the sixty patients studied were as follows, median age at 
diagnosis was 64 years (range 30-81), fifty two percent (n=31) of the tumors were 
located on the right side of the colon and 53% (n=32) of the patients were male. The 
majority 70% (n=42) had a T3 tumor. Median follow up was 39 months (range 2-57). 
40% was still alive without evidence of disease at the end of the follow up, 24% had 
developed a local recidive or a distant metastasis, 31% was dead because of cancer 
related causes and 5.2% was dead because of non cancer related causes as specified in 
their medical records. Median time to progression was 15 months (range 6-47)
Frequencies of the different alleles are shown in table 1. All frequencies followed 
Hardy-Weinberg equilibrium and did not differ significantly from frequencies published 
on the HapMap database for the Caucasian population. 
In this group of patients, there were no significant associations between any of the 
genotypes found and any of the clinical and histopathological variables tested including 
gender, tumor location, T stage and N stage. 
Survival Analysis
For the survival analysis, TYMS SNP genotypes were grouped as putative high TS 
expression (genotypes 2R/3G, 3C/3G and 3G/3G) and putative low TS expression 
(2R/2R, 2R/3C. 3C/3C). No effect on progression free survival of the several genotypes 
was seen in a univariate (figure 1) or in a multivariate survival analysis, containing other 
known prognostic variables for colon carcinoma such as T stage and N stage of the 
tumor. 
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Log Rank  GG vs. AA p=0.75
GG vs. AG p=0.85 
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c)
 Log Rank GG vs. AA p=0.97 
 GG vs. AG p=0.82 
d)
 Log Rank  2R/2R vs. 2R/3R p=0.41  





Figure 1: Kaplan Meier plots for PFS according to all genotypes tested; a) TYMP 
G6601A genotypes, b) OPRT G638C, c) DPYD A1627G, d)TYMS 28bp VNTR, e) TYMS 
expression category determined by SNP genotypes (Low expression 2R/2R, 2R/3C, 
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Discussion
We aimed to study whether known SNPs in genes involved in 5-FU metabolism were 
good markers of therapy response in stage III colon carcinoma patients. According to 
our results, we conclude that the SNPs tested in the OPRT, TYMP, TYMS and DPYD 
genes are not good markers of therapy response in the present cohort. No effect on 
survival of the different genotypes was seen, however, results should be considered 
with caution due to the small number of patients analyzed.
Although, increased expression of OPRT mRNA and protein activity have been related 
to a shorter survival of colorectal carcinoma patients treated with 5-FU 10-12 together 
with the fact that the studied SNP has been proven to be associated to a higher protein 
expression and activity 13 4, no effects of the different genotypes in DFS was seen in the 
present cohort. The OPRT CC variant is very rare in the general population. Our results 
reflect the low frequency of this genotype in the Caucasian population. If the CC variant 
would have an effect on survival, the fact that it is such a rare variant makes it very 
difficult to prove since numbers of patients needed would be very large.
The existing literature is more conclusive about TP protein expression which seems 
to have no influence in survival of colorectal patients 14-19. Accordingly, the SNP in the 
TYMP gene was not a good marker for therapy response in our group. 
The role of the typed polymorphisms on the TYMS gene remains controversial. It has 
been widely studied as protein and mRNA expression as well as DNA genotyping, still 
the results are inconclusive as reviewed by Popat et al 7. These contradictory results 
are probably due to differences in methodology, technology and patients’ selection. In 
the present patient group, TYMS polymorphisms in the enhancer region are not good 
markers of therapy response, even when grouping patient by category of putative 
TS expression no difference in survival was found between putative low and high 
producers. These results agree with previous results in a larger cohort of patients 20.
Finally, although DPYD has been widely studied in relation to 5-FU toxicity, it also 
seemed to have a role in outcome 15,19,21-23. However, whether this effect is due to the 
enzyme itself or due to high toxicity and subsequent therapy interruption is not clear. 
In the present cohort of patients, the studied SNP is not a good marker of therapy 
response.
In conclusion, polymorphisms in genes involved in 5-FU metabolism are not valuable 





results of a clinical trial over the value of some polymorphisms in predicting toxicity in 
a large group of colon carcinoma patients failed to find any relation between the tested 
SNPs and toxicity 1. In that study the value of several SNPs involved in 5-FU metabolism 
was tested in relation to toxicity. In the same way, we cannot show any value of these 
SNPs as markers of response to 5-FU in our group of patients.
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Abstract
Adjuvant chemotherapy improves survival in stage III colon cancer patients. However, 
a subgroup of patients still develops recurrent disease at some point in time, partly 
because of the ineffectiveness of the chemotherapy. Predictive markers of response 
are therefore crucial. Our aim was to study the predictive value of functional 
polymorphisms in genes involved in the metabolism of oxaliplatin and in DNA repair in 
stage III colon cancer patients.
Normal DNA was isolated from 98 patients diagnosed with stage III colon carcinoma. 
Single nucleotide polymorphisms (SNPs) in three genes (the excision repair cross-
complementing genes ERCC1 19007T>C and ERCC2 2251A>C, and the glutathione 
S-transferase pi 1 gene GSTPI 313A>G were tested by PCR followed by digestion with 
restriction enzymes or by direct sequencing. These genes and SNPs were selected on 
the basis of their reported associations with oxaliplatin response in colorectal cancer.
The genotype frequencies were in Hardy-Weinberg equilibrium. GSTPI and ERCC2 
polymorphisms were significantly associated with sex. The AA genotype of GSTPI 
313A>G was more frequent in men than in women (59% vs 30%, p = 0.02). The CC 
genotype of ERCC2 2251A>C was significantly more frequent in women than in men 
(24% vs 6%, p = 0.02). In univariate and multivariate survival analysis, none of the tested 
polymorphisms seemed to influence disease-free survival. The GSTPI AA genotype 
had different effects on survival between men and women; homozygous A men had 
significantly worse cancer-specific survival and overall survival than women with the 
same genotype (log rank p = 0.029 and p = 0.015, respectively).
None of the tested polymorphisms is likely to be a reliable marker of response to 
oxaliplatin therapy. The GSTPI 313A>G homozygous A genotype may have a prognostic 






Oxaliplatin was approved for adjuvant treatment of stage III colon carcinoma patients 
in the Netherlands in 2004. When administered in combination with fluorouracil, 
this platinum compound has been proven to decrease the recurrence risk by 23% in 
the first 3 years after surgery and to increase overall survival by 4.2% after 6 years 
of follow-up1-3. Age and the presence of comorbidity are known factors limiting the 
use of chemotherapy, even when chemotherapy is advised according to guidelines4,5. 
In this regard, patients with stage III disease form a very interesting study group, 
since chemotherapy is given in an adjuvant setting to increase survival by decreasing 
recurrence rates. Thus, in stage III disease, chemotherapy has the potential to be 
curative. Within this disease stage, markers of response are essential to increase 
therapy success rates and decrease toxicity due to unnecessary exposure to drugs.
The mechanism of action of platinum compounds is through the generation of DNA 
platinum adducts, leading to intrastrand crosslinks. Thereafter, DNA synthesis will 
be inhibited and the cell will undergo apoptosis3. Two main mechanisms are involved 
in oxaliplatin resistance: on one hand there is increased intracellular detoxification, 
mediated by glutathione-S-transferase proteins; and on the other hand there is 
increased activity of the nucleotide excision repair system, which is involved in repairing 
DNA damage specifically caused by oxaliplatin6,7.
Several polymorphisms in the genes coding for detoxification enzymes (glutathione 
S-transferase pi 1 [GSTPI], glutathione S-transferase theta 1 [GSTT1], and glutathione 
S-transferase mu 1 [GSTM1]) and the nucleotide excision repair system (excision repair 
cross-complementing rodent repair deficiency, complementation group 2 [ERCC2], 
excision repair cross-complementing rodent repair deficiency, complementation 
group 1 [ERCC1], X-ray repair complementing defective repair in Chinese hamster cells 
1 [XRCC1], and xeroderma pigmentosum, complementation group A [XPA]) have been 
studied in the context of resistance to platinum compounds8,9 in different types of 
cancer such as colon carcinoma, head and neck tumors10, esophageal cancer11, and 
lung cancer12. The use of different study designs, control groups, cancer types, and 
therapies makes the study results difficult to interpret and often discordant.
In the case of colon carcinoma, the single nucleotide polymorphisms (SNPs) ERCC1 
19007T>C (Asn118Asn), ERCC2 2251A>C (Lys751Glyn), and GSTP1 313A>G (Ile105Val) 
have been frequently studied and associated with response to oxaliplatin, but mostly 
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in metastatic colorectal cancer where patients receive several lines of combination 
therapy3,8,9,13-19.
However, findings on the effects of these SNPs on protein production – and, more 
importantly, on protein function – have been inconclusive. For the GSTP1 313A>G 
polymorphism only, a consensus has been reached regarding the functional 
consequences, i.e. the variant allele is associated with decreased conjugating activity3. 
The functional findings on ERCC1 19007T>C and ERCC2 2251A>C have been more 
controversial. Although ERCC1 19007T>C is a synonymous SNP which does not cause 
amino acid substitution, ERCC1 expression has been shown to be decreased in patients 
with the variant allele (19007C) 20. The functional reports on the effects of the 2251A>C 
SNP in ERCC2 have been contradictory. One study concluded that homozygous C would 
have less DNA repair capacity in the lung 12, whereas other researchers have reported 
suboptimal DNA repair capacity in homozygous A 21. Despite the unclear functional 
role of these SNPs and the inconsistent results obtained in metastatic colon cancer 
patients, we aimed to determine the predictive value of the three SNPs – namely, 
ERCC1 19007T>C, ERCC2 2251A>C, and GSTP1 313A>G – in stage III colon cancer 







Patients (n = 98) with stage III colon carcinoma diagnosed at the Pathologic Anatomy 
and Medical Microbiology (PAMM) Laboratory (Eindhoven, the Netherlands) were 
included in this retrospective study. All patients were treated with curative intended 
surgery followed by adjuvant chemotherapy. Fifty-three patients (54%) followed either 
the FOLFOX regimen (leucovorin, bolus fluorouracil, and oxaliplatin) or the XELOX 
(oxaliplatin and oral capecitabine) regimen, whereas 45 patients (46%) followed the 
Mayo regimen (leucovorin and bolus fluorouracil). The median age and sex distribution 
did not differ significantly between these two groups. Demographic data were obtained 
from the cancer registry managed by the Comprehensive Cancer Centre South 
(Integraal Kankercentrum Zuid [IKZ]; Eindhoven, the Netherlands). Clinical data were 
obtained from the patients’ medical records between April 2009 and January 2010. 
The median follow-up period was 37 months (range 2–57 months). The use of clinical 
material for this retrospective study was approved by the local institutional review 
board, according to the guidelines of the Dutch Federation of Biomedical Scientific 
Societies (FMWV), reviewed in January 2009.
DNA was isolated from formalin-fixed paraffin-embedded normal colonic mucosa, 
using an HPTPP kit (Roche, Almere, the Netherlands) after proteinase K digestion, 
according to the manufacturer’s instructions.
Single Nucleotide Polymorphism Typing
ERCC1 19007T>C
This SNP, consisting of a T>C transition at codon 118 (rs11615) was typed by means 
of PCR and restriction fragment length polymorphism. PCR was performed using the 
following primers: forward 5’GCA GAG CTC ACC TGA GGA AC3’ and reverse 5’GAG GTG 
CAA GAA GAG GTG GA3’, as described elsewhere8.Subsequently, the PCR products were 
digested with the BsrDI restriction enzyme (New England Biolabs, Hitchin, UK), which 
digests the product into two fragments of 117 bp and 82 bp in length, respectively, if 
the T allele is present.
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ERCC2 2251A>C
The ERCC2 2251A>C SNP (rs13181), causing the substitution of lysine with glutamine in 
codon 751, was determined by PCR followed by direct sequencing. To briefly summarize, 
PCR was performed using the following primers: forward 5’TGC CCC CCT CTC CCT TT 
3’ and reverse 5’CCA GGG CCA GGC AAG ACT 3’. The PCR products were subsequently 
purified using ExoSAP-IT (USB Europe GmbH, Staufen, Germany), according to the 
manufacturer’s instructions. Thereafter, a sequencing reaction was performed using 
Applied Biosystems chemistry (Applied Biosystems, Nieuwerkerk aan den IJssel, the 
Netherlands). Finally, sequence products were analyzed on an Applied Biosystems ABI 
3130, using sequencing analysis software from Applied Biosystems.
GSTP1 313A>G
The GSTP1 polymorphism in codon 105 (rs1695), causing the substitution of isoleucine 
with valine, was typed by means of PCR and subsequent restriction enzyme digestion. 
First, PCR was performed with the following primers: forward 5’ACC CCA GGG CTC TAT 
GGG AA3’ and reverse 5’TGA GGG CAC AAG AAG CCC CT3’, as published elsewhere 8. A 
single product of 176 bp in length was obtained, which was subsequently digested with 
the BsmAI restriction enzyme (New England Biolabs). Two products of 88 bp each were 
obtained after digestion of the G allele, whereas the product remained undigested 
when the A allele was present.
Statistical Analysis
All statistical analyses were performed using the SPSS v.16 package for Windows 
(Chicago, IL, USA).
A χ2 test and Fischer exact tests were performed to study associations between 
categorical variables. One-way analysis of variance was used to study associations 
between categorical and continuous variables.
To study the predictive value of the variables that were tested, we chose as primary 
end points disease-free survival, defined as the time between curative surgery and the 
development of either a distant metastasis or a local recurrence, and cancer-specific 
survival, defined as the period of time from curative surgery until cancer-related death. 
As a secondary end point, overall survival was defined as the time between curative 
surgery and death from any cause.





between curves were analyzed using the log-rank method. Hazard ratios and 
multivariate analysis were calculated using the Cox proportional hazard model. All 
tests were two-tailed, and the results were considered significant when p ≤ 0.05.
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Results
The patient characteristics, allelic frequencies, and associations between variables are 
presented in table 1. In summary, the median age was 64 years (range 30–85 years), 59 
of 98 patients (60%) were male, 52 of 98 tumors (54%) were located on the right side of 
the colon (between the coecum and the splenic flexure), and 64 (65%) were classified 
as T3 tumors. The median follow-up period was 37 months (range 2–57 months). At 
the end of the follow-up period, 46 patients (47%) had no evidence of cancer, 21 (22%) 
were alive with cancer, 26 patients (27%) had died from cancer-related causes, and 
4 patients (4%) had died from non-cancer-related causes, according to their medical 
records.
Because of the poor DNA quality in some samples or PCR inhibition, not all samples 
could be analysed for all three SNPs.
All genotypes that were studied were in Hardy-Weinberg equilibrium. The allelic 
frequencies of all three SNPs were in agreement with frequencies published for 
Caucasian populations on the website of the US National Institute for Biotechnology 
and Information (www.ncbi.nlm.nih.gov; reviewed in October 2010). A significant 
association was found between ERCC2 2251A>C and sex. The CC genotype was more 
frequent in women than in men (24% vs 6%, p = 0.02). Moreover, the GSTP1 313A>G 
SNP was also significantly associated with sex. Men were more frequently homozygous 
A than women (59% vs 30%, p = 0.02). No further statistically significant associations 
between the studied variables were found.
No significant effects of any of the tested polymorphisms on clinical outcomes were 
seen (figure 1 shows disease-free survival; cancer-specific survival and overall survival 
are not shown).
In the multivariate survival analysis, which included sex and age in the model, none of 
the SNPs were associated with a higher hazard ratio for disease-free survival, cancer-
specific survival, or overall survival (table 2 shows disease-free survival).
Because of the significant association between ERCC2 2251A>C and GSTP1 313A>G and 
sex, we also analyzed the effects of these polymorphisms on survival according to sex. 
There was no significant interaction between the ERCC2 2251A>C polymorphism and 
sex in relation to disease outcome. Conversely, GSTP1 313A>G seemed to influence 
prognosis differently in men than in women; homozygosity A conferred significantly 





0.03 for cancer-specific survival and p = 0.0015 for overall survival) as compared with 
the other genotypes (figure 2), but no such effect on disease-free survival was seen. 
This association was independent of the therapy received by the patients.
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Patient category and therapy HR 95% CI p-value
ERCC1 19007T>C
Fluorouracil + oxaliplatin (N = 48)
   male sex 2.65 0.94, 7.45 0.06
   Age 0.97 0.91, 1.03 0.32
   ERCC1 TT Reference
   ERCC1 CT 0.67 0.23, 1.89 0.45
   ERCC1 CC 0.94 0.26, 3.36 0.92
Fluorouracil + leucovorin (N = 36)
   male sex 0.69 0.25, 1.94 0.49
   Age 0.97 0.91, 1.03 0.34
    ERCC1 TT Reference
    ERCC1 CT 1.42 0.51, 3.97 0.5
    ERCC1 CC 1.95 0.31, 12.11 0.47
ERCC2 2251A>C
Fluorouracil + oxaliplatin (N = 43)
   male sex 2.16 0.64, 7.35 0.22
   age 0.99 0.93, 1.07 0.96
    ERCC2 AA Reference
    ERCC2 AC 0.65 0.24, 1.8 0.41
    ERCC2 CC 0.73 0.13, 4.11 0.72
Fluorouracil + leucovorin (N = 32)
   male sex 0.86 0.32, 2.34 0.77
   Age 0.95 0.9, 0.99 0.04
    ERCC2 AA Reference
    ERCC2 AC 1.25 0.47, 3.33 0.65
    ERCC2 CC 2.04 0.43, 9.68 0.37
GSTPI 313A>G
Fluorouracil + oxaliplatin (N = 50)
   male sex 2.8 0.97, 8.03 0.06
   Age 0.96 0.91, 1.02 0.17
   GSTPI AA Reference
   GSTPI AG 2.1 0.84, 5.25 0.11
   GSTPI GG 1.57 0.31, 7.9 0.59
Fluorouracil + leucovorin (N = 42)
   male sex 1.23 0.51, 2.97 0.65
   Age 0.97 0.92, 1.02 0.23
   GSTPI AA Reference
   GSTPI AG 0.9 0.35, 2.28 0.80
   GSTPI GG 0.41 0.05, 3.15 0.4
Table 2: Cox proportional hazard model for disease-free survival in patients with the 
three SNPs that were tested.
CI = confidence interval; ERCC1 = excision repair cross-complementing rodent repair deficiency, 
complementation group 1; ERCC2 = excision repair cross-complementing rodent repair deficiency, 







TT vs. CT:  p=0.41
TT vs. CC: p=0.4
CC vs. CT: p=0.53
b)
TT vs. CT: p=0.41
TT vs. CC: p=0.43
CC vs. CT: p=0.54
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Figure 1: Kaplan-Meier plots for disease-free survival (a, c and e) in patients receiving 
combination therapy with fluorouracil and oxaliplatin, and (b, d and f) in patients 
treated with fluorouracil alone: (a and b) patients with the ERCC1 19007T>C SNP; (c 
and d) patients with the ERCC2 2251A>C SNP; and (e and f) patients with the GSTP1 
313A>G SNP. 
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Discussion
The studied SNPs were selected on the basis of previously published results showing 
an association between these SNPs and oxaliplatin response in advanced colorectal 
carcinoma 8,9. However, not all reports agree on the predictive value of these SNPs 
in oxaliplatin response. Moreover, most research has been performed in advanced 
colorectal carcinoma where therapy is palliative; therefore, in this study, we aimed 
to determine the effects of the ERCC1 19007T>C, ERCC2 2251A>C, and GSTPI 313A>G 
polymorphisms in response to oxaliplatin administered in an adjuvant setting. In order 
to answer this question, survival according to the different SNPs and the therapy given 
were analyzed in a cohort of patients with stage III disease. From the present data, it 
can be concluded that none of the SNPs studied here are good markers of response to 
oxaliplatin given in the adjuvant setting.
In a recent meta-analysis, Yin et al. concluded that ERCC1 19007T>C had predictive 
value as a marker of response to oxaliplatin therapy, however, their analysis included 
studies of gastric cancer as well as colorectal cancer 9. Considering colorectal cancer 
solely, the existing findings on the predictive value of ERCC1 19007T>C are rather 
inconclusive. Taking previous findings together with the data presented in this study, 
it can be concluded that ERCC1 19007T>C is not a reliable marker of response to 
oxaliplatin in colon carcinoma patients 8,18,19.
Our findings on the ERCC2 2251A>C SNP showed that this SNP is not a reliable 
predictive marker of response to adjuvant oxaliplatin therapy either. The predictive 
value of this polymorphism is controversial; some researchers have found that the A 
allele is predictive of a better outcome 8,14,15, whereas others have demonstrated the 
opposite 10,11. In the present cohort of patients, no effects of ERCC2 2251A>C were 
seen. A possible explanation for these contradictory findings could be that all of these 
studies, including ours, were retrospective studies, and most of them were conducted 
in metastatic colorectal cancer patients treated with several lines of therapy. Thus, 
prospective studies in homogeneous patient populations must be carried out to 
elucidate the clinical value of these markers.
Finally, although the findings on the GSTPI gene polymorphism in this study contradict 
those in other reports 8, they corroborate the findings of Kweekel et al. 22 in stage IV 
colon cancer. Therefore, we conclude that it is likely that the GSTP1 313A>G SNP has no 





In our study, certain genotypes were associated with sex and conferred worse 
overall survival in males than in females. Sex is a well known prognostic factor in 
colorectal cancer, and the reasons for sex-related survival advantages are not yet fully 
understood23-25. The association found here between certain polymorphic alleles and 
sex – and the possible effects of the polymorphisms on cancer susceptibility, prognosis, 
and response to therapy – could at least partly explain sex-related survival differences. 
Recently, it has been proposed that sex should be taken into account when evaluating 
predictive markers of response, as these markers have been found to be different for 
males and females 26.
Finally, we would like to stress the importance of prospective studies with enough 
statistical power to confirm whether or not these SNPs have value as predictive markers 
in clinical practice.
None of the polymorphisms studied in the present project seemed to be a reliable 
predictive marker of response to adjuvant oxaliplatin therapy. It seemed, however, that 
the GSTPI 313A>G homozygous A genotype had a prognostic effect in male patients, 
independently of the treatment given.
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Abstract
Molecular markers in colon cancer are needed for a more accurate classification and 
personalized treatment. We determined the effects on clinical outcome of the BRAF 
mutation, microsatellite instability (MSI) and KRAS mutations in stage II and III colon 
carcinoma.
Stage II colon carcinoma patients (n=106) treated with surgery only and 258 stage III 
patients all adjuvantly treated with 5-FU chemotherapy, were included. KRAS mutations 
in codons 12 and 13, V600E BRAF mutation and MSI status were determined.
Older patients (p<0.001), right sided (p=0.018), better differentiated (p=0.003) and MSI 
tumors (p<0.001) were significantly more frequent in stage II than stage III. 
In both groups, there was a positive association between mutated BRAF and MSI 
(p=0.001) and BRAF mutation and right sided tumors (p=0.001). Mutations in BRAF and 
KRAS were mutually exclusive. 
In a multivariate survival analysis with pooled stage II and III data BRAF mutation 
was an independent prognostic factor for overall survival and cancer specific survival 
(HR=0.45 95%CI 0.25 – 0.8 for OS and HR=0.47 95%CI 0.22 – 0.99). KRAS mutation 
conferred a poorer DFS (HR=0.6 95%CI 0.38 – 0.97).
The V600E BRAF mutation confers a worse prognosis to stage II and III colon cancer 






Colon carcinoma is classified according to clinical and histopathological criteria. 
Prognosis and therapy relate to this classification. According to the Dutch treatment 
guidelines previous to 2006, stage II patients were solely treated with surgery. Stage III 
patients would receive adjuvant chemotherapy after surgery. Around 20% of stage II 
patients will develop a relapse in the first five years after surgery. Probably, this group of 
patients would benefit from adjuvant chemotherapy. On the other hand, 60% of stage 
III patients are cured after surgery and do not benefit from the adjuvant treatment 1 2. 
Hence, other criteria for adjuvant therapy are needed. Molecular markers might prove 
to be better than clinical and histopathological criteria for therapy selection. 
Microsatellite instability (MSI) and KRAS mutations have been widely studied in 
colorectal cancer. Around 20% of the sporadic colon cancers show MSI due to defects 
in the mismatch repair system (MMR). MSI is associated with a better prognosis3-6. 
Approximately 35% of colon cancers carry a mutation in codons 12 or 13 of the 
KRAS gene leading to the constitutive activation of its downstream pathway and to 
uncontrolled cell division 7-9. BRAF is recently being studied in relation to prognosis10-13. 
BRAF is a downstream effector molecule of KRAS. 90% of the BRAF mutations consist 
in a valine to glutamate transition at position 600 of the protein, the so called V600E 
mutation, which causes the constitutive activation of the protein. This mutation is 
found in approximately 20% of the colonic tumors. 
Mutations in BRAF and in KRAS are mutually exclusive. Tumors harboring the V600E 
BRAF mutation have other clinical and histopathological features than KRAS mutated 
tumors 14. 
The value of KRAS mutations in stage II and III is unknown. BRAF has been studied only 
in heterogeneous colon carcinoma patients cohorts including all disease stages 10-12 and 
recently in a group of stage IV colorectal cancer 13. To date, it remains unknown what 
the effect of the BRAF mutation is on clinical outcome of patients with either stage II 
or III disease. 
In this study we aimed to determine the status of the V600E BRAF mutation and other 
molecular markers, like MSI status and KRAS mutations in two well defined groups 
of stage II and III colon carcinoma patients who were treated according to the Dutch 
guidelines previous to 2006 and to assess their effect on patient outcome.
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Three hundred sixty four patients diagnosed at the PAMM Laboratory for Pathology in 
Eindhoven, the Netherlands and treated in four different regional hospitals in the south 
of the Netherlands, between 1996 and 2004, were included in this study. We included 
106 patients diagnosed with stage II colon carcinoma and treated with surgery only 
and 258 stage III disease patients treated with surgery followed by adjuvant 5-FU in 
combination with leucovorin chemotherapy like established by the Dutch guidelines 
for the treatment of colon cancer previous to 2006. A tumor was considered right sided 
when it was located between the coecum and the splenic flexure. The remaining tumors 
were considered left sided. Rectal tumors were not included. Demographic and clinical 
data on the patients were facilitated by the Cancer Registry of the Comprehensive 
Cancer Centre South (IKZ, Eindhoven, the Netherlands). In over 93% of the patients 
data was complete. Follow-up was obtained from the available medical records of the 
patients.
The use of clinical material for this retrospective study was approved by the institutional 
review board according to the guidelines of the Dutch Federation of Research 
Associations.
From all patients with sufficient available material, tumor DNA was isolated. For this 
purpose, a tumor area with at least 30% tumor cells from glass slide according to 
HE stained sections was selected by an experienced pathologist. Subsequently, the 
selected areas were macrodissected from archival paraffin embedded tissue. DNA 
was purified after proteinase K digestion with the HPPTP kit (Roche, Almere, the 
Netherlands) following manufacturer’s instructions. 
From 76 patients data were missing due to different reasons, firstly some tissue blocks 
were not present in our archive (47.4%), secondly some samples did not reach 30% 









the following primers and probes, forward 5’CTA CTG TTT TCC TTT ACT TAC TAC ACC 
TCA GA 3’ and reverse 5’ATC CAG ACA ACT GTT CAA ACT GAT G 3’, wild type probe VIC-
5’CTA GCT ACA GTG AAA TC 3’ and mutant probe FAM-5’TAG CTA CAG AGA AAT C 3’ 
like described elsewhere15. A PCR product of 136 bp was obtained. The assay showed to 
have a detection limit of at least 10% tumor cells in a given specimen. All PCR reactions 
were performed on the Light Cycler v2.0 (Roche, Almere, the Netherlands) using Roche 
chemistry in a total volume of 20 microliters. 
Microsatellite instability
Microsatellite instability was detected using only one marker of the Bethesda panel, i.e. 
the mononucleotide repeat BAT26. This marker was chosen because in the Caucasian 
race, it detects 99% of the MSI high patients and normal DNA is not necessary 16,17. 
PCR was performed using the following primers, forward VIC-5´TGA CTA CTT TTG ACT 
TCA GCC 3´ and reverse 5 ÁCC CAT TCA ACA TTT TTA ACC C 3 .́ The expected product 
length is 116 bp. Subsequently, PCR products were diluted depending on their intensity 
and denatured using formamide and incubated at 95°C for 3 minutes. Products size 
were analyzed using the ABI3130 (Applied Biosystems, Nieuwerkerk aan de Ijssel, the 
Netherlands) and GeneMapper 4.0 software package.
KRAS mutation analysis 
Mutations in codons 12 and 13 of the KRAS gene were detected by DNA sequencing. 
Briefly, PCR amplification of the cited codons was performed using the following 
primers; forward 5 ÁGG CCT GCT GAA AAT GAC TG 3 ánd reverse 5´TCA AAG AAT GGT 
CCT GCA CC 3´ as previously described by van Zandwijk et al 18. The expected product 
length was 172 bp. After purification of the PCR product, the sequence reaction was 
performed using the same primers independently and the Big Dye reagents (Applied 
Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands). Products were separated on 
the ABI3130 (Applied Biosystems, Nieuwerkerk aan de Ijssel, the Netherlands). The 
sequences were evaluated with the Sequencing Analysis 5.3.1 software.
Statistical Analysis
SPSSv.16 software for Windows (Chicago, IL) was used. X2, Fischer exact tests and 
Student’s t-test were used to analyze the relationship between variables. 
Stage II and stage III groups were first analyzed separately and pooled during survival 
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analysis to increase the sensitivity of the tests. Univariate survival analysis was 
performed with Kaplan Meier analysis and survival curves were compared by Log-Rank 
tests. Multivariate analysis was performed with Cox Proportional Hazards regression 
analysis. T and N stage, but also age, sex, tumour location, differentiation grade, BRAF, 
KRAS, and MSI status were included in the model. In case of statistical significant 
interaction between these variables in the model, we would stratify the analyses 
accordingly. We considered a minimum of 10 to 15 events per predictor necessary to 
proceed with multivariate survival analyses 19. In order to avoid overfitting, all variables 
were entered and maintained in the model, e.g. not using automated stepwise 
regression. For the same reason, those variables which did not exhibit a statistically 
significant relation with survival in the univariate analysis were also entered into the 
model. Besides, variables in isolation may behave quite differently with respect to 
the response variable when they are considered simultaneously with 1 or more other 
variables 20. Overall survival (OS) was defined as the time between diagnosis and either 
death of disease or death of other cause, whenever this was specified in the patients’ 
medical record. Disease free survival (DFS) was defined as the time between diagnosis 
and disease recurrence or development of distant metastasis. Finally, cancer specific 







Patients’ demographic and clinicopathological characteristics
Patients’ characteristics according to stage are shown in table 1. 
By definition none of the patients diagnosed with stage II disease had tumor positive 
lymph nodes whereas all of the stage III patients had positive lymph nodes. In both 
groups a similar number of lymph nodes were examined for diagnosis, median number 
of 7 in stage II and of 8 in stage III.
In the stage II group median age was 73 years (range 30-94) whereas in the stage 
III group it was 64 years (range 30-84). This difference was statistically significant 
(p<0.001).
The tumor location was also significantly different between groups, 68% right sided 
tumors in stage II vs. 54% in stage III (p=0.018). Well or moderately differentiated 
tumors were more frequent in stage II patients than in stage III (87% in stage II vs. 72% 
in stage III, p=0.005).
The cause of death was significantly different between groups. In the stage II group 
30% of the patients had died because of reasons other than cancer (as specified in their 
medical records) and 10% due to cancer related reasons. In the stage III group only 
7% had died of non-cancer related causes and 32% died due to cancer related causes 
(p<0.001).
Median follow up of the stage II group was 55 months (0-109) and 46 months (2-133) 
for the stage III group. 
KRAS, BRAF and MSI status
Table 2 a&b shows the frequencies of the different mutations in the patient population 
and the significant associations between variables for the two patients’ populations. 
The percentages of the mutations in KRAS and BRAF did not differ between the two 
populations. KRAS mutations were found in 33% of stage II patients vs. 35% of stage 
III. BRAF was mutated in 22% of stage II and in 19% of stage III patients. However, the 
proportion MSI tumors was significantly higher in the stage II group than in stage III 
(25% vs. 14%, respectively, p=0.024).
KRAS and BRAF mutations were mutually exclusive (p<0.001) in both populations. 
There was no significant association between KRAS mutations and the development of 
a distant metastasis or local relapse in stage II patients (p=0.08). Moreover, it did reach 
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statistical significance in stage III patients (p=0.014). KRAS mutations were associated 
to better differentiated tumors (p=0.013 stage II and p=0.06 stage III).
The carriage of the V600E BRAF mutation was significantly associated with MSI 
(p<0.001), right side location (p<0.001) in both populations. 
In both groups MSI tumors were right sided (p=0.003 stage II and p<0.001 stage III) and 
poorly differentiated (p=0.024 stage II and p=0.022 stage III). 
Survival analysis
In a univariate analysis, in both groups separately the BRAF V600E mutation was 
significantly associated with a shorter CSS in stage II disease (p=0.022) but not in stage 
III disease (Figure 1). In both groups there was a trend towards a longer OS for the 
carriers of wild type BRAF (p=0.194 stage II and 0.069 stage III) (Figure 2). DFS was not 
significantly different between BRAF mutants and wild type tumors.
When stratifying for MSI status, BRAF mutation resulted in shorter survival in MSS 
patients in both stage II and stage III disease (p=0.011 stage II CSS and p=0.016 stage III 
OS), but not in the MSI group.
In the stage III group, KRAS mutations seemed to confer a significantly worse DFS than 
KRAS wild type (p=0.03) (Figure 3). This effect was not present in the stage II group.
Multivariate analysis
Since results did not significantly differ between both populations, data of both 
groups were pooled in order to increase sensitivity of the multivariate analysis. A 
Cox Proportional Hazards model including differentiation grade, age as a continuous 
variable, sex, tumor location, T-stage, N-stage, KRAS status, BRAF status and MSI status 
was used. The results of this model are shown in table 3. Therapy was not included in 
the model because it covariates linearly with N-stage. 
BRAF mutation was as an independent factor for a shorter OS (HR=0.45 95%CI 0.25-
0.8), DFS (HR=0.43 95%CI 0.22-0.82) and CSS (HR=0.47 95%CI 0.22-0.99). KRAS mutation 
was an independent prognostic factor for a shorter DFS (HR=0.6 95%CI 0.4-0.97). T- 
stage was a prognostic factor for DFS, OS and CSS. N-stage, as positive or negative 
lymphnodes, was prognostic for DFS and CSS. Finally, male gender was a significant 
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Figure 1: Kaplan Meier plots for CSS in stage II and in stage III patients according to 





Figure 2: Kaplan Meier plots for CSS according to BRAF V600E mutational status in the 
whole group stratified according to MSI status of the tumor.
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Discussion
The molecular signature of a tumor will most likely influence patient survival. In stage 
II and III colon cancer the use of molecular markers might be particularly important 
in order to offer the most adequate therapy to each patient and avoid unnecessary 
chemotherapeutic treatment. In this study, we assessed the effect of the V600E BRAF 
mutation, KRAS mutations and MSI on patient outcome, in two well defined colon 
cancer populations of stage II and III patients.
In our population, the V600E BRAF mutation is an independent prognostic factor. 
The carriage of the mutation accounts for a significantly higher risk of dying of cancer 
related causes, independently of other factors like age, sex, location of the tumor, MSI 
status, KRAS mutational status, differentiation grade, T-stage and N-stage. 
Our results agree with recent published studies from Ogino et al. and Tol et al. However, 
Ogino et al. found a relationship between BRAF mutation and CSS in an heterogeneous 
group of colon cancer patients including all disease stages 11, whereas, our study focus 
solely on a well described homogeneous stage II and III group. On the other hand, 
Tol et al. demonstrated a positive correlation between the V600E BRAF mutation and 
a shorter survival in a group of metastatic colorectal patients independently of the 
treatment arm (capecitabine, oxaliplatin, bevacizumab with or without cetuximab) 13. 
However, the patients included in that study did all receive palliative chemotherapy 
and therefore no conclusion could be drawn about either the prognostic or predictive 
value of the BRAF mutation. From our data, we can conclude that the BRAF mutation 
is an independent prognostic factor in all patients with stage II and III colon carcinoma. 
It could be argued that our selection of patients based on the therapy according to the 
guidelines could bias the results. However, identical results were obtained in a larger 
group including stage III patients who did not receive adjuvant chemotherapy (data not 
shown).
Moreover, concordant with the literature 10,12, the V600E BRAF mutation identifies 
a small group of patients with microsatellite stable tumors who had a poor survival. 
However, the interaction between MSI, BRAF and disease outcome remains subject of 
study since in the multivariate analysis, MSI seemed to play a marginal role depending 
on therapy in patients’ survival.
The presence of a KRAS mutation did not have any effect on patient overall survival 





KRAS mutated and wild type tumors. The prognostic value of KRAS mutations in 
stage II and III colon carcinoma remains controversial. Many studies have reported a 
prognostic role for KRAS and many others failed to report this effect, as reviewed by 
Castagnola21. Based on our results we can conclude that KRAS seems to play a role in 
disease progression, mainly in stage III colon cancer patients, this effect is absent in 
stage II patients.
In our study, a group of stage II patients, who did not receive adjuvant therapy 
after surgery and a group of stage III patients who did receive 5-FU based adjuvant 
chemotherapy according to the Dutch guidelines previous to 2006 were selected. This 
treatment selection is the major reason for the differences in age and follow up status 
between patients in the two groups. It is known that only younger patients with a good 
general condition and little co-morbidity are offered adjuvant chemotherapy. Since 
all stage III patients in our group received chemotherapy, they were younger and had 
less comorbidity and thus less non-cancer related deaths than stage II patients, who 
frequently died of non cancer related deaths like heart failure.
Other significant differences between the two groups were the frequency of MSI and 
of right sided tumors in the stage II group. For the MSI determination, we choose the 
mononucleotide repeat BAT 26, because it discriminates 99% of MSI in the Caucasian 
population without the requirement of amplified normal DNA, like previously 
described17. The use of only one marker could have diminished the sensitivity of our 
analysis but not the specificity 16,17. The higher frequency of MSI tumors in stage II is 
probably due to the significant association of MSI and right sided tumors and the higher 
proportion of these tumors among stage II patients which in turn can be explained by 
the shift in tumor location that occurs as patient age increases 22. 
Due to the retrospective character of this study, we were not able to test patients 
who were treated according to the recently published Dutch guidelines where a 
difference in treatment is made between stage II and high risk stage II. Since 2006, high 
risk stage II patients receive adjuvant chemotherapy after surgery. High risk stage II 
patients are defined as having pT4 lesions, lymphovascular invasion, tumor perforation 
or obstruction, poorly differentiated histology, or less than 10 lymph nodes removed. 
Eighty four percent of our stage II patients would be nowadays considered as high 
risk patients. The majority due to the insufficient number of lymph nodes examined. 
Therefore, we can conclude that the negative effects of the V600E BRAF mutation 
on survival are applicable to this group of patients and that this mutation can be 
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considered as a prognostic marker.
In conclusion, BRAF is an independent prognostic factor in stage II and III colon 
cancer. These results are promising for the treatment of colon cancer patients since 
determination of the V600E BRAF mutation can discriminate between patients who 
have a shorter OS, DFS and CSS. The exact effect of MSI and of KRAS on survival should 
be further elucidated. In contrast, this BRAF mutation might become an important 
molecular marker in the future for drug development and in the decision making for 
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Abstract
PIK3CA mutations in the helical domain (exon 9) and in the kinase domain (exon 20) 
cause tumor formation by different means. We aimed to determine the effects of each 
of these mutations on survival of colon carcinoma patients. 
A large cohort of 685 colon carcinoma patients was tested for PIK3CA mutations in 
exons 9 and 20 by single nucleotide primer extension (N=428) or by real time PCR 
(N=257).
PIK3CA mutation rate was 13%. 66 of 83 (79.5%) were in exon 9 and 17 of 83 (20.5%) in 
exon 20. In survival analysis, PIK3CA mutations in exon 9 and 20 had different effects 
on patient outcome. The PIK3CA exon 20 mutation conferred a poorer disease free 
survival compared to patients with wild type alleles and exon 9 mutations (Log rank 
p=0.04 and p=0.03 respectively) and cancer specific survival (Log rank p=0.03 and 
p=0.056 respectively) in stage III patients. In stage I and II this negative effect on 
outcome was not seen. 
PIK3CA mutation in exon 20 is a negative prognostic factor in stage III colon cancer 






Tumor classification according to the UICC’s or AJCC’s TNM classification is the most 
important prognostic factor in colorectal cancer. According to treatment guidelines, 
adjuvant chemotherapy is given to patients with stage III disease and with high risk 
stage II disease. High risk stage II is defined as T4 tumors, clinical presentation as bowel 
obstruction or perforation, poor differentiation or lymph node yield of less than ten. 
In these stages, adjuvant chemotherapy improves significantly 5 years survival rates1,2. 
One could argue, though, that some stage III patients could be considered cured 
after surgery alone and thus do not benefit from the adjuvant chemotherapy and are 
therefore overtreated. Opposed to the 15% of the node negative stage II patients that 
do relapse, as this group would probably benefit from adjuvant chemotherapy and 
are therefore undertreated 2. To identify these patients, accurate markers of disease 
prognosis are needed. Over the last decade, several informative molecular prognostic 
and/or predictive markers have been identified in stage II and III colon cancer patients, 
such as microsatellite instability (MSI) and chromosome 18q deletion 3-8. Recently, the 
BRAF V600E mutation was also defined as an important prognostic factor in these 
patients 9,10. 
This search for molecular markers has led to study the mutational status of proteins 
involved in cellular transduction pathways signaling for cell survival and proliferation. 
An important protein involved in many cellular functions such as cell proliferation, 
growth and apoptosis is the phosphatidyl-inositol 3 kinase catalytic subunit alpha 
(PIK3CA), also known as p110α 11-13. PIK3CA is an activating protein kinase, which 
phosphorylates PIP2 into PIP3 facilitating the activation of AKT and further downstream 
signaling to activate mTOR. PIK3CA forms an heterodimer with its regulatory subunit 
p85α, which stabilizes PIK3CA and inhibits its kinase activity 13. Nevertheless, binding 
with p85α is mandatory for PIK3CA activation. PIK3CA is frequently mutated in several 
malignancies like thyroid, mama, colon and pancreas cancer 14. Mutated PIK3CA has 
been found to be oncogenic 15 and to promote disease progression and metastasis 
in colon cancer models 16. Mutation frequencies in colon carcinoma vary from 16 to 
37%14,17-19. The most frequent mutations in the PIK3CA gene occur in codons 542 and 
545 in exon 9 coding for the helical domain and in codon 1047 in exon 20 coding for the 
kinase domain. These mutations all induce a gain of function of PIK3CA but they drive 
cancer progression through different pathways 20. To induce transformation exon 20 
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mutants depend on binding with the regulatory subunit p85α whereas exon 9 mutants 
circumvent p85α binding but depend on RAS binding instead 13,21,22. 
Moreover, these mutations could represent phenotypically different histological types 
of cancer. In breast cancer, for instance, exon 9 mutations were significantly associated 
with lobular carcinomas 23. Besides, PIK3CA exon 20 mutations were found almost 
exclusively in hereditary colon carcinoma forms such as Lynch syndrome and familial 
adenomatous polyposis (FAP); whereas in sporadic forms, exon 9 mutations were 
significantly more frequent 24.
In colon carcinoma, the prognostic value of PIK3CA mutations is controversial. Several 
authors have reported a negative prognostic effect of PIK3CA mutations 18,25 whereas 
others are unable to reproduce these data 26. However, till recently mutations have not 
been studied independently. Therefore, the aim of the present study was to determine 
the impact of the mutations either present in the helical or in the kinase domain of 







Six hundred and eighty five patients diagnosed with stage I (n=49), stage II (n=223) and 
stage III (n=413) colon carcinoma between 1990 and 2006 were included in this study. 
The majority of the patients (N=456, 67%) were diagnosed between 1997 and 2004, 
166 (24%) were diagnosed prior to 1997 and 63 (9%) between 2004 and 2006. Four 
hundred twenty eight patients (62.5%) were diagnosed at the PAMM laboratory for 
Pathology and treated in four different hospitals in the Eindhoven region in the south 
of the Netherlands. Whereas two hundred fifty seven patients (37.5%) were diagnosed 
and treated at the Leiden University Medical Centre (LUMC), Leiden, the Netherlands. 
The 428 patients from Eindhoven are hereafter called the PAMM cohort and the 257 
patients from Leiden, the LUMC cohort.
Of the stage II patients, 131 (58%) would nowadays be considered as high risk stage 
II mostly due to the insufficient number of lymph nodes examined at the time of 
diagnosis and would therefore receive adjuvant chemotherapy. From these high risk 
patients only 6 (4%) were treated with adjuvant chemotherapy as well as four patients 
with stage II disease. Of the stage III patients, 296 received adjuvant chemotherapy. In 
total, 306 patients (45%) received adjuvant chemotherapy after surgery whereas 371 
(54%) did not. Data from eight patients on adjuvant chemotherapy was missing (1%).
A tumor was considered right sided when it was located between the coecum and the 
splenic flexure. A left sided tumor was located between the splenic flexure and the 
rectosigmoid. Rectum tumors were excluded from the study since these patients are 
treated differently from colon cancer patients.
Demographic data were obtained from the database of the Eindhoven Cancer Registry 
maintained by the Comprehensive Cancer Centre South. Follow-up data were collected 
from the medical records and the Oncdoc registration at the LUMC. 
Patient’s characteristics of the entire group are depicted in Table 1. Briefly, median age 
was 68 years (22-94), 53% (N=362) was male, and 53% (N=352) had a right sided tumor. 
The majority of the patients had a T3 (N=481; 71%), well or moderately differentiated 
(N=456; 76%) and microsatellite stable tumor (N=498 82%). Median follow up was 49 
months (0-219) and median time to progression was 44 months. At the end of the 
follow up period, 49% of the patients were still alive without evidence of disease, 7% 
was alive with disease whereas 24% had died because of cancer related causes and 
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20% had died because of causes other than cancer as specified in their medical records.
The use of clinical material for this retrospective study was approved by the institutional 
review boards according to the guidelines of the Dutch Federation of Medical Research 
Associations (www.fmww.nl viewed January 2009).
Tumor tissue was selected by experienced pathologists (GvL, HM) using diagnostic 
hematoxyline-eosine (HE) slides. Tumor cell percentages of at least 30% tumor 
cell were set. This cut-off value is higher than the analytic detection limits of both 
techniques used. Subsequently, selected areas were macrodissected or punched 
with a 2mm core needle. DNA was isolated after proteinase K digestion of formalin 
fixed paraffin embedded tissue (FFPE) and subsequent purification with either HPTTP 
kit (Roche, Almere, the Netherlands) or Nucleospin Tissue (Macherey Nagel, Düren, 
Germany) following manufacturer’s instructions with minor modifications.
Mutation analysis
In the PAMM cohort, PIK3CA mutations were determined by PCR followed by single 
nucleotide primer extension assay, as described by Hurst et al. 27 for the hotspots in 
exon 9, c.1624G>A; p.E542K and c.1633G>A; p.E545K and in exon 20 the c.3140A>G; 
p.H1047R. Briefly, both exons were amplified by multiplex PCR. After enzymatic 
purification of the PCR products with EXO SAP (USB Co, Staufen, Germany), the 
extension reaction was performed using primers published elsewhere 27 and the ABI 
Prism® SNaPshot™ multiplex kit (Applied Biosystems, Nieuwerkerk aan den IJssel, 
the Netherlands). Finally, these products were purified and separated by capillary 
electrophoresis using an ABI 3130 (Applied Biosystems, Nieuwerkerk aan den IJssel, 
the Netherlands).
In the LUMC cohort, PIK3CA mutation detection of the same hotspots was performed 
by real time PCR enabling allelic discrimination using primers and probes designed 
and ordered by Applied Biosystems and TAQMAN chemistry (Applied Biosystems, 
Nieuwerkerk aan den IJssel, the Netherlands). Assays were performed in a Roche Light 
Cycler 480 (Roche, Almere, the Netherlands) (manuscript in preparation).
In 69 (10%) samples, mutations could not be typed due to poor DNA quality after 
isolation. However, missing data were equally distributed between groups and was not 
a source of bias (see table 1). 
Sensitivity was not an issue in this study, as all of the samples tested contained more 





1-10% tumor cells. To test specificity and sensitivity, several samples were tested with 
both techniques and compared with direct sequencing. No discrepancies were found. 
 The existence of a putative pseudogene on chromosome 22 overlapping exon 9 to 13 
of the PIK3CA gene does not influence our results because the mutations studied here 
correspond to E545K and E542K which are not present in the pseudogene. 
In the PAMM cohort, MMR status, mutations in BRAF V600E and KRAS codons 12 and 
13 had been previously determined and described 10.
In the LUMC cohort MMR status was determined with the multiplex kit, MSI Analysis 
System version 1.2. (Promega, Madison, WI, USA). Products were separated by capillary 
electrophoresis using an ABI 3130 (Applied Biosystems, Nieuwerkerk aan den Ijssel, the 
Netherlands).
Statistical analyses
All statistical analyses were performed using SPSS version 16 software for Windows 
(Chicago, Il, USA). 
To study associations between categorical variables χ2 test and Fisher’s exact test 
were used. Associations between categorical and continuous variables were studied 
by ANOVA. Univariate and multivariate survival analyses were performed by Kaplan 
Meier and Cox Proportional Hazards method. Survival curves were compared using the 
Log Rank method.
Disease Free Survival (DFS) is defined as the time between surgery and disease 
progression being the development of distant metastasis or local recurrence or death 
due to cancer related causes whatever happened first. Cancer Specific Survival (CSS) 
is the period of time between surgery and death because of cancer related causes. 
Overall survival (OS) is defined as the period of time between surgery and death 
because of any cause.
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PIK3CA mutations were found in 83 (13%) patients. In the majority of the patients 
(N=66; 79.5%) the mutation was located in exon 9, the helical domain coding region 
and in 17 (20.5%) cases a mutation was detected in exon 20, the kinase domain coding 
region. No double mutants were found in the whole cohort.
In the present cohort of patients PIK3CA mutations were associated with MMR status. 
MSI-H tumors had significantly more frequently a PIK3CA mutation in exon 20 (p=0.006) 
(Table 1). 
The frequencies of the additionally typed mutations in the PAMM cohort were as 
follows: 34% KRAS mutations in codons 12 and 13 and 21% BRAF V600E mutation as 
previously described 10. There were no significant associations found between these 
mutations and PIK3CA mutations (Table 2).
Survival analyses
Univariate analysis
All PIK3CA mutations together did not influence survival in the present group of 
patients. OS, DFS and CSS did not differ between wild type and mutant patients. 
However, the effect of each of the PIK3CA mutations on CSS and DFS differed. PIK3CA 
exon 9 mutations did not affect survival in the studied disease stages, whereas PIK3CA 
exon 20 mutations conferred a poorer DFS and CSS to stage III patients only (DFS Log 
Rank wt vs. exon 20 p=0.04 and exon 9 mutation vs. exon 20 p=0.03; CSS Log Rank wt 
vs. exon 20 mutation p=0.03 and exon 9 mutations vs. exon 20 mutation p=0.056). 
This negative effect in patient’s outcome of the latter mutation was not seen in stage 
I and II. As the survival curves from stage I and stage II did not differ, both stages were 
grouped for the survival analysis and were compared with stage III tumors (CSS Kaplan 
Meier plot is shown in Figure 1). The lack of negative effects in survival of the exon 20 
mutation in stage I and II disease was maintained in the high risk stage II group (Figure 
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Median age (min-max) 68 (22-94) 68 (30-94) 68 (30-93) 67 (35-94) 67 (45-84)
Median Follow-up in 
months (min-max)
49 (0-219) 49 (0 – 219) 49 (0-219) 47.5 (0-177) 48 (9-124)
Disease Progression
   No progression











Table 1: Patient’s characteristics and association with PIK3CA mutations.
* It was not possible to perform DNA mutation analysis in 10% of the patients as described in 
materials and methods.  
#p=0.006
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Multivariate analysis: Cox Proportional Hazards model
In a multivariate survival analysis adjusting for age, gender, tumor location, adjuvant 
chemotherapy, T stage, MMR status and tumor differentiation, PIK3CA mutations in 
exon 20 were significant negative prognostic factors in stage III tumors (CSS HR 4.53 
95% CI 1.56 – 13.2 p=0.006), whereas in stage I and II tumors no significant effect 
was seen (Table 3). PIK3CA exon 9 mutations did not affect survival neither in the 
multivariate analysis. 
In a multivariate survival analysis in the PAMM cohort adjusting for the above 
mentioned prognostic variables and adding BRAF V600E mutation, KRAS codon 12 and 
13 mutation, the negative effects of the PIK3CA exon 20 mutation on DFS, CSS and OS 
remained significant in the stage III group. In the stage I and II group, PIK3CA exon 20 
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Table 2: KRAS and BRAF mutations frequencies and associations with PIK3CA 
mutations in the PAMM cohort.
§ It was not possible to perform DNA mutation analysis in 10% of the patients as described in 





a) Stage I and II
wt N=186  exon 9 N=23 exon 20 N=9
Log Rank wt vs. exon9 p=0.93; wt vs. exon20 p=0.24; exon9 vs.exon20 p=0.21
b) Stage III
wt N=326  exon 9 N=42  exon 20 N=7
Log Rank wt vs. exon9 p=0.94; wt vs. exon 20 p=0.029; exon 9 vs. exon 20 p=0.056
Figure 1: Kaplan Meier plots in a)stage I and stage II and b) stage III disease for Cancer 
Specific Survival according to PIK3CA mutations.
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wt N=83  exon 9 N=8  exon 20 N=5
Log rank wt ex9 p=0.4, wt ex20 p=0.5 
wt N=91 exon 9 N=12 exon 20 N=4
Log rank wt ex9 p=0.6, wt ex20 p=0.3, ex9 ex20 p=0.25
a) Stage I and II





wt N=326 exon 9 N=42 exon 20 N=7
Log rank wt ex9 p=0.9, wt ex20 p=0.03, ex9 ex20 p=0.06
Figure 2: Kaplan Meier plots for Cancer Specific Survival in a) stage I and II, b) high risk 
stage II and c)stage III according to PIK3CA mutation.
c) Stage III
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Overall Survival Variables in the model HR p-value 95% CI
Stage I and II
(N=149)
PIK3CA
   PIK3CA wt referent
   PIK3CA exon 9 0.86 0.85 0.19 - 4
   PIK3CA exon 20 0 0.91 0– 2.2E68
T status
   T2 referent
   T3 13266.33 0.95 0 – 1.2E119
   T4 63038.4 0.94 0 – 1.4E120
Category differentiation
   Well/moderately diff. 
   Poor/Undiff.
referent
1.52 0.57 0.36 – 6.34
Adjuvant chemotherapy 
   No
  Yes
referent
3.09 0.24 0.48 – 20.08
Age 1.02 0.34 0.98 – 1.07
Gender
   Male
   Female
referent
1.62 0.32 0.63 – 4.1
Tumor Location
   Right sided
   Left sided 
referent
0.91 0.87 0.3 – 2.78
MMR status
   MSS
   MSI-H
`
referent




   PIK3CA wt referent
   PIK3CA exon 9 1.11 0.77 0.55 – 2.22
   PIK3CA exon 20 4.53 0.006 1.56 – 13.2
T status
   T2 referent
   T3 0.042 0.002 0.005 – 0.33
   T4 0.50 0.005 0.31 – 0.81
Category differentiation
   Well/moderately diff. 
   Poor/Undiff.
referent
1.6 0.05 0.99 – 2.74
Adjuvant chemotherapy
   no
   yes
referent
0.68 0.19 0.38 – 1.21
Age 1.001 0.91 0.98 – 1.03
Gender
   Male
   Female
referent
0.98 0.92 0.63 – 1.52
Tumor Location
   Right sided
   Left sided
referent
1.16 0.54 0.73 – 1.83
MMR status
   MSS
   MSI-H
referent
0.73 0.35 0.38 – 1.41
Table 3: Cox proportional hazard model for CSS in the whole group.






Hotspot mutations in PIK3CA causing the constitutive activation of the protein, 
contribute to cell transformation and tumor progression. Mutations in the helical and 
the kinase domain cause cellular transformation and tumor progression by different 
means20,21,23,28-32. Until recently, the impact on colon cancer survival of these different 
mutations has not been studied.
To study the effects of the different mutations separately, a large cohort of patients 
was mandatory. This need implied collecting material through a relatively broad period 
of time i.e. 1990-2006. During this period, colon cancer treatment protocols and 
guidelines changed improving survival. However, the improvement in survival trends 
for stage II disease took place before 1995 and for stage III survival improvement was 
mainly due to the introduction of adjuvant chemotherapy in the mid nineties 33,34. 
Therefore, this issue does not influence the results as the majority of the patients 
studied were diagnosed after 1995 and administration of chemotherapy was one of 
the variables corrected for in the multivariate model. 
In the present cohort of colon carcinoma patients, the PIK3CA mutations in exon 9 
and in exon 20 had different effects on survival. Mutations in exon 9 did not affect 
survival, whereas exon 20 mutations had a negative effect on survival but only in stage 
III patients. Only recently, the prognostic value of PIK3CA mutations in colon cancer 
was studied segregating both mutation types. De Roock and colleagues 35 published 
an interesting report over several gene mutations involved in resistance to anti-EGFR 
therapy in metastatic colorectal carcinoma. These authors concluded that only PIK3CA 
exon 20 mutations influenced survival of a group of patients with metastatic colorectal 
cancer chemotherapy refractory treated with chemotherapy and cetuximab. Our 
findings support the theory of a different effect of exon 20 and exon 9 mutations on 
survival. The data of de Roock et al together with the present data could explain the 
inconclusive results previously published on colon cancer survival with respect to the 
effect of PIK3CA mutations18,25,26. 
Furthermore, in the present study we described what might be a stage dependent 
survival effect, as mutations in exon 20 conferred a poor survival but only in stage 
III disease whereas this deleterious effect was not present in stage I/II patients with 
PIK3CA exon 20 mutations. This trend was maintained in the stage II high risk group. 
As it could be expected based on the described association between exon 20 mutations 
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and Lynch syndrome 24, mutations in the kinase domain were significantly more 
frequent in MSI-H tumors. An interesting question is whether microsatellite instability 
confounds the results on outcome of patients with exon 20 mutations. Microsatellite 
instability confers a better prognosis to stage II and to stage III if not treated with 
5-FU 3,8. From our analyses it can be concluded that the prognostic effects of exon 20 
mutations are independent of the microsatellite status of the tumor as survival effects 
of these mutations were seen in both groups of patients MSI-H and MSS. 
The biological background of this stage dependent prognostic effect could be explained 
by the fact that the PIK3CA protein mutated in its kinase domain must necessarily bind 
to its regulatory subunit p85α in order to have transforming capacities 13,22. Although, 
p85α is not frequently found mutated in human cancer, its expression is altered. 
Indeed, p85α is differentially expressed in adenoma tissue compared to carcinomas 
as shown by immunohistochemistry in colonic tissue. Moreover, expression of p85α 
increases as well with disease stage 36 and is highly overexpressed in node positive 
tumors 37 whereas PIK3CA exon 20 mutations frequency do not differ significantly 
among different stages. Thus, it could be hypothesized that through the low levels of 
expression of the regulatory subunit in stage I and II tumors, exon 20 PIK3CA might 
not have enhanced tumorigenic capacity and hence the better survival of this group of 
patients, whereas in stage III tumors, tumorigenic capacity would be present resulting 
in a poorer outcome. This hypothesis is currently under investigation.
This study has the limitations inherent to its retrospective character and to the frequency 
of exon 20 mutations; therefore validation of these data in a larger retrospective cohort 
or preferably in a prospective study is necessary in order to confirm the potentially 
relevant clinical consequences of this study. 
Targeted therapies inhibiting PIK3CA signaling are currently under investigation in 
clinical trials 38. However, if our results are confirmed, individual PIK3CA mutations 
should be assessed and correlated to disease stage since patients with early stages 
disease carrying PIK3CA exon 20 mutations seemed to have a better natural history of 
their disease and further treatment might be unnecessary. On the other hand, stage 
III patients with PIK3CA exon 20 mutations would probably benefit from additional 
targeted therapies.
In conclusion, the prognostic value of mutations in the PIK3CA gene is different according 
to the type of mutation. Mutations in exon 9 do not influence outcome whereas exon 





stage I and II patients however, the same mutation did not have any negative effect on 
survival. Moreover, the lack of deleterious effects on outcome is also present in a high 
risk stage II patient’s population and might therefore harbor true clinical implications. 
In future studies addressing the mutational status of PIK3CA both hotspots should be 
analyzed separately.
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Abstract
p53 (encoded by TP53) is involved in DNA damage repair, cell cycle regulation, apoptosis, 
aging and cellular senescence. TP53 is mutated in around 50% of human cancers. 
Nevertheless, the consequences of p53 inactivation in colon cancer outcome remain 
unclear. Recently, the role of p53 together with CSNK1A1 in colon cancer invasiveness 
has been described in mice. 
By combining data on different levels of p53 inactivation, we aimed to predict p53 
functionality and to determine its effects on colon cancer outcome. Moreover, survival 
effects of CSNK1A1 together with p53 were also studied.
Eighty-three formalin fixed paraffin embedded colon tumors were enriched for tumor 
cells using flow sorting, the extracted DNA was used in a custom SNP array to determine 
chr17p13-11 allelic state; p53 immunostaining, TP53 exons 5, 6, 7 and 8 mutations were 
determined in combination with mRNA expression analysis on frozen tissue.
Patients with a predicted functional p53 had a better prognosis than patients with 
non functional p53 (Log Rank p=0.009). Expression of CSNK1A1 modified p53 survival 
effects. Patients with low CSNK1A1 expression and non-functional p53 had a very 
poor survival both in the univariate (Log Rank p<0.001) and in the multivariate survival 
analysis (HR=4.74 95% CI 1.45 – 15.3 p=0.009).
In conclusion, the combination of genetic, genomic, protein and downstream 
transcriptional activity data is very informative of p53 functionality. The predicted p53 







During colon carcinogenesis cells accumulate several genetic and genomic aberrations 
that lead to uncontrolled proliferation and tumor formation 1. A major event in the 
adenoma to carcinoma transition is TP53 inactivation. p53 plays a crucial role in 
maintaining genome stability and integrity. Upon DNA damage, the activation of p53 
leads to cell cycle arrest enabling the cells to repair the damaged DNA. On the other 
hand, when the damage is too extensive to be repaired p53 activation can also drive the 
cell towards apoptosis or senescence 2. Recently, p53 has also been implicated in tumor 
invasiveness 3. In mice, the inactivation of casein kinase 1 alpha (Csnk1a1) promotes the 
cytoplasmatic/nuclear accumulation of β-catenin which stimulates the transcription 
of Wnt signaling target genes. The combined inactivation of p53 and Csnk1a1 rapidly 
leads to tumor invasiveness in the colon of these mice.
Inactivation of TP53 is one of the most frequent events in human cancer 4. Among 
others, TP53 can be inactivated by “loss of function” mutations in one allele and 
deletion of the remaining wild type allele or by dominant negative mutations that are 
able to inactivate also the wild type protein transcribed by the second unaffected allele. 
Either way, when p53 function is jeopardized, genomic instability and uncontrolled cell 
proliferation are facilitated. 
The role of p53 inactivation in colon cancer progression and prognosis has been widely 
studied but remains elusive notwithstanding the amount of reports addressing this 
subject 5-17. Chromosomal instability (CIN) is a known prognostic factor in colon cancer18. 
Although TP53 inactivation has been frequently associated with CIN, not all tumors 
with CIN carry an inactive p53 and vice versa 19. More complexity is added by the recent 
demonstration that TP53 can behave as a haploinsufficient tumor suppressor gene. 
Using mouse models, Ventakachalam and coworkers demonstrated that mice carrying 
one functional p53 allele developed tumors but they showed however a milder 
phenotype than mice that lost both alleles 20. Moreover, several reports described the 
TP53 gene dosage effect on expression of target genes 21, 22. 
Recent developments in genomic copy number analysis have shown to more accurately 
study the measure of chromosomal structural and numeric aberrations 23. The 
development of the lesser allele intensity ratio (LAIR) algorithm that integrates the DNA 
index in the analysis of copy number data gives a real measure of the chromosomal 
alterations and allows the study of gene dosage effects in tumors. 
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Given the complexity of the p53 network, the several ways of p53 inactivation, and 
the recently described role of p53 in cancer invasiveness in mice, we studied in detail 
different levels of p53 inactivation in human colon cancer taking into account the allelic 
state of the locus on the short arm of chromosome 17, gene mutation state, protein 
expression levels, downstream target gene expression and determine the prognostic 
impact in colon cancer patients. Moreover, interactions with the recently described 







Eighty three colorectal cancer patients diagnosed as stage I, II or III at the Leiden 
University Medical Centre between 1991 and 2005 were selected for the present study. 
Methods
Tissue preparation for multiparameter flow cytometry and sorting
Tumor and stromal cells were sorted from FFPE tissue blocks using the FACS ARIA I 
(BD Biosciences, San Jose, CA, USA) based on vimentin, keratin and DNA content as 
previously described by Corver et al 24, 25. DNA index (DI) defined as the ratio between 
the median G0/G1 keratin fraction and the median G0/G1 vimentin fraction, was 
calculated using a remote link between Winlist and ModFit (Verity Software House) 
for each sample. Whenever more than one keratin positive clone was seen, it was 
independently sorted. DI was categorized as DI< 0.95; DI=0.95 – 1.05; DI=1.06 – 1.4; 
DI=1.41 – 1.95 and DI>1.95.
DNA was purified from sorted cells after an overnight proteinase K digestion using the 
Nucleospin Tissue kit (Macherey Nagel, Düren, Germany) following manufacturer’s 
instructions. 
SNP array hybridization for allelic state determination
A custom Golden Gate genotyping panel with 384 SNPs was designed using the Assay 
Design Tool (Illumina Inc. San Diego, CA, USA). The panel contains SNPs mapping the 
the following chromosomes: 1q21-25, 8q22-24, 13q12-34, 17p13-11 (the TP53 locus), 
18q12-22 and 20q11-13, all of which are associated with tumor progression in the 
colorectum 26. SNPs on chromosome 2 serve as controls. Paired samples were analysed 
in the Golden Gate assay as described 27 and hybridized to Sentrix Array Matrix with 
384 bead types. SNP arrays were analysed in the BeadarraySNP package. The data 
generated was analyzed with the LAIR algorithm 23 that integrates the DNA index into 
the analysis. We differentiated the following allelic states: 1) genotype AB or normal; 2) 
genotype A or loss of heterozygosity (LOH); 3) copy neutral LOH (CN LOH) or genotype 
AA; 4) amplified LOH (amp LOH) corresponding to genotype AAA or AAAA; 5) allelic 
imbalance (AI) or genotype AAB, AAABB; 6) balanced amplification (BA) corresponding 
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Figure 1: 
a) Schematic representation of the possible allelic states according to LAIR scores 
b) Example of a DNA histogram of one tumor containing two clones with different 
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to AABB genotypes and finally multiclonal samples whenever more than one clone was 
seen by flow cytometry (Figure 1)23.
FISH 
To confirm the copy number results obtained with the SNP array, FISH in nuclei obtained 
from FFPE material of seven patients was performed. First, 2mm. punches (Beecher 
Instruments, Silver Springs, MD, USA) of selected tumor areas were embedded 
in blanco acceptor paraffin blocks. Subsequently, 50 µM slices were obtained, 
deparaffinized and rehydrated. Antigen retrieval was performed by high pressure 
cooking in Tris-EDTA pH=9. After incubation for one hour at 37°C with RNAse, samples 
were digested with 0.5% pepsin pH=2 at 37°C for 30 minutes. The obtained nuclei 
were then washed and resuspended in methanol: acetic acid in a 3 to 1 proportion. 
Thereafter nuclei were spun onto clean glasses and hybridization with Vysis® TP53/
CEP17 FISH probe kit (Abbot Molecular, IL, USA) was allowed overnight at 37°C. After 
washing, samples were mounted with Vectashield® mounting medium containing DAPI 
(Vector Laboratories Inc., Burlingame, CA, USA) and nuclei were evaluated under the 
fluorescence microscope.
Seven patients were tested from whom enough material was available and with 
different allelic states of chr.17p according to the SNP array analysis. 
p53 IHC staining
Tissue microarrays (TMA) of these tumors were prepared by punching three 
representative tumor areas selected by a pathologist (HM) on HE stained slides and 
arraying them on a recipient paraffin block (Beecher Instruments, Silver Springs, 
MD, USA). Five µM slices were then cut. Heat induced antigen retrieval (HIAR) was 
performed as described elsewhere 26 and staining was carried out with the mouse anti-
human monoclonal antibodies directed against p53 (clone D0-7, 1:1000 dilution) (Lab 
Vision NeoMarkers, Fremont, CA, USA).
p53 was scored in four different categories based on any level of nuclear staining: 
completely negative; 1- 25% positive nuclei (indicative of a wild type state); 25-75% 
positive nuclei and >75% positive nuclei. For analysis purposes, the last two categories 
were fused in only one category; more than 25% positive cells (indicative of a mutated 
gene).
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TP53 mutation analysis
Tumor DNA was isolated from enriched tumor areas containing at least 50% tumor cells 
by proteinase K digestion followed by purification with Nucleospin Tissue kit (Marcherey 
Nagel, Düren, Germany). DNA was available from 40 patients. Four different PCRs were 
performed for amplification of exons 5, 6, 7 and 8 of the TP53 gene. Ten nanograms 
DNA were used for each PCR using primers already published modified for SYBRgreen® 
detection 28. Subsequently, PCR products were purified using Qiagen’s MinElute™96 
UF PCR Purification Kit (Qiagen Sciences, Germantown, MD, USA) and reactions were 
sequenced using the MI13 forward and reverse primers. Analysis was performed using 
the Mutation Surveyor 3.97® sequence analysis and assembly software (SoftGenetics 
LLC, Stage College, PA, USA).
mRNA expression arrays
Fresh frozen tissue of fifty seven patients was available for mRNA expression analysis. 
mRNA was isolated, labeled and hybridized to customized Agendia 44 K oligonucleotide 
array as described elsewhere 29. The expression of the 35 genes reported by Yoon et 
al22 as genes which expression is TP53 gene dosage dependent was analyzed in relation 
with p53 functional state. Furthermore, expression levels of three probes targeting 
different locations in the 3’UTR of the CSNK1A1 gene (NM_001025105.1 transcript) 
were independently analyzed. 
Finally, expression levels of eight genes reported by Elyada et al (3) as involved in 
murine tumor invasiveness were also analyzed.
Statistical analysis
Associations between categorical variables were studied by χ2 and Fischer exact test. 
Univariate survival analysis was performed by Kaplan Meier analysis and differences 
between survival curves were studied by Log Rank analysis. Multivariate survival 
analysis was performed by Cox Proportional Hazard Model. Cancer Specific Survival 
was defined as the time between curative intended surgery and dead by cancer related 
causes. Results were considered significant when p value <=0.05. All tests were two 
tailed. All of the analyses mentioned above were performed using SPSSv16 package for 
Windows (Chicago, Il, USA)
Statistical analysis of the mRNA expression data was done using the LIMMA (Linear 







Patients’ characteristics are shown in table 1. Summarized, 54% of the patients were 
female, 63% of the tumors were right sided (i.e. tumors located in the colon from the 
coecum until the splenic flexure) and 37% left sided. 4% of the patients had stage I 
disease at diagnosis, 61% stage II and 35% stage III. Twenty seven tumors were MSI-H 
(33%), whereas 55 (67%) were MSS tumors.
Median follow up was 69 months (range 2 – 199). At the end of the follow up, 41% of 
the patients were alive, 24% of the patients had died because of cancer related causes 
and 30% died because of non cancer related causes. 
Allelic state
All samples were flow cell sorted as previously described and analyzed with a costum 
SNP array comprising several chromosomal regions previously reported to be implicated 
in colorectal cancer progression 26. In the present study we have focused on the allelic 
state of the TP53 locus on chromosome 17p13-11. Of the 83 tumors analyzed, 47% 
were classified as normal with genotype AB, 11% as LOH (genotype A), 13% as CN LOH 
(genotype AA), 8% as amp LOH (genotype AAA/AAAA) and 4% as AI (genotype AAB/
AAABB). Note also that 17% of the patients showed multiple cancer clones by flow 
cytometry (results shown in table 1). No balanced amplification corresponding to AABB 
genotypes was seen in the monoclonal series. LAIR scores were determined by four 
observers independently.
The LAIR scores of four samples randomly selected were confirmed by FISH (figure 2). 
Three out of 83 samples with discordant LAIR scores between the observers were also 
assessed by FISH for the definitive categorization.
Predicted p53 functionality
The predicted functionality of p53 (hereafter called functionality) was determined for 
each sample by combining data from the TP53 locus allelic state, mutation data and 
protein expression levels. 
Associations between p53 functionality and the different variables are shown in table 
2. Summarizing, the majority of functional p53 (78%) had no mutation in TP53 (p=0.01) 
and all of them had between 0-25% positive stained cells using immunohistochemistry 
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(p<0.0001). 78% of the tumors with functional p53 had a near diploid DNA index raging 
from 0.95-1.05 whereas 63% of the non functional p53 samples was highly aneuploid 
with DNA indexes ranging 1.41 – 1.95 (p<0.001). Samples with a functional p53 had 
significantly more frequently the normal AB genotype, than amp LOH (genotype AAA/
AAAA) (p=0.005), CN LOH (genotype AA) (p<0.001) and than tumors with two clones 
(p=0.006). Moreover, functional p53 was also more frequently seen in the LOH class 
(genotype A) than in the CN LOH class (genotype AA) (p=0.01). Tumors with a functional 
p53 were significantly more frequently right sided tumors (p=0.035). Eighty six percent 
of the tumors with non functional p53 were MSS tumors (p=0.009).
To corroborate the classification in functional and not functional p53, we compared 
p53 target gene expression levels between these two groups. We selected genes 
which expression was previously shown to be p53 gene dosage dependent by Yoon 
et al 22. Eight genes differently expressed between both groups were identified (table 
3). As expected, known p53 targets like MDM2 and CDKN1A were higher expressed in 
the p53 functional group than in the non functional group (p=0.0025 and p=0.0013 
respectively). Genes higher expressed in the non functional group were involved in 
many processes such as cell proliferation (PRKCZ), protein ubiquitination (SIAH1), 





Characteristics Total N (%)
Age
   50-59
   60-69
   70-79






   Male




   Right




   I and II




   MSS




   AB
   LOH
   CN LOH
   Amp LOH
   AI








   0.95 – 1.05
   1.06 – 1.40





   wt




   0 %
   >0% - ≤25%




Table 1: Patients’ characteristics.
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LAIR chr 2: AB               LAIR chr.17: A                 FISH: two centromeres and one TP53 
                                                                                  copy
Sample 1: DNA index=1.1 
             
a)                                                                             b) 
Sample 2: DNA index=2.3 
             
a)                                                                             b) 
LAIR chr. 2: AABB         LAIR chr.17 AAAA          FISH: four centromeres and four TP53 
                                                                                  copies
Figure 2: Results of a) SNP array on reference chromosome and chr.17p 
b) FISH on Chr. 17 (the green signal corresponds to the centromere probe and the red 
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   0
   0 - ≤25% 








Chr. 17 p status
   AB
   LOH
   Copy neutral LOH
   Amplified LOH
   Allelic Imbalance















   50 – 59
   60 – 69
   70 – 79











   0.95 – 1.05
   1.06 – 1.4









   MSI







   Male







   Right







   I and II






Table 2: Associations between clinicopathological variables and p53 functionality.
*Χ2 test allelic status AB vs. LOH p=0.58; AB vs. CN LOH p<0.001; AB vs. Amp LOH p=0.005; AB vs. two 
clones p=0.006; LOH vs. CN LOH p=0.01; LOH vs. Amp LOH p=0.24; LOH vs. two clones p=0.28; Amp LOH 
vs. CN LOH p=0.43; Amp LOH vs. two clones p=1; CN LOH vs. two clones p=0.48
# Χ2 test p53 IHC 0 vs. 0-25% p=0.07; 0 vs. >25% p<0.001; 0-25% vs. >25% p=0.001
¶ Χ2 test DNA index 0.95 – 1.05 vs. 1.06 – 1.4 p=0.16; 0.95 – 1.05 vs. 1.41- 1.95 p<0.001; 1.06 – 1.40 vs. 
1.41 – 1.95 p=0.29
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Patient survival analysis 
In a univariate survival analysis, p53 functionality was prognostic, patients with 
functional p53 had a better cancer specific survival than patients with non functional 
p53 (Log rank p=0.009) (figure 3). 
In the present cohort of patients, MSI-H was somewhat more frequent than expected 
from epidemiological studies (33% vs. 18% expected), nevertheless MMR status did 
not influence survival (data not shown) nor the effects of p53 functionality on survival.
Recently, the role of p53 and Csnk1a1 inactivation in tumor invasiveness in mice 
has been demonstrated 3. We analyzed whether the expression levels of CSNK1A1 
influenced p53 effects in disease outcome. For each of the three probes analyzed 
(A_23_P213551; A_24_P183292; A_24_P251899) patients were divided according to 
the expression level in high expression when expression level was greater than the 
median value for that specific probe and low expression when the value was lower than 
the median. The values of the three probes correlated significantly with each other 
(Pearson’s correlation coefficient =0.94 p<0.001 between A_23_P213551 and A_24_
P251899, 0.747 p<0.001 between A_23_P213551 and A_24_P183292 and finally 0.743 
p<0.001 between A_24_P183292 and A_24_P251899) (figure 4). The three probes 
had the same detrimental effect on survival in a univariate analysis with different 
significant p values (data not shown). We selected the probe (A_24_P183292) with the 
most significant results (Log rank p=0.003) for further analyses.
CSNK1A1 expression significantly altered the effect of p53 in survival as shown in figure 
5. CSNK1A1 had no influence on survival when p53 is functional, however, if patients had 
a non functional p53, CSNK1A1 expression influenced disease outcome dramatically. 
Patients with low CSNK1A1 expression had a very poor prognosis compared with 
patients with high CSNK1A1 expression (Log rank p=0.007) (figure 5). 
We then classified patients in two categories based on p53 functionality and CSNK1A1 
expression; i.e. patients with non functional p53 and low CSNK1A1 expression and the 
rest of patients (non functional p53 and high CSNK1A1 expression or functional p53 
with high or low CSNK1A1 expression). Patients with both genes affected died earlier 
than patients with one of both genes active (figure 6) (Log rank p<0.001). Moreover, 
this detrimental effect on disease outcome was significant in a multivariate model 
including tumor stage, gender, tumor location and MMR status in the model (HR=4.74 
95%CI 1.47-15.34 p=0.009) (Table 4).
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Expression of invasiveness genes
Next we analyzed expression of eight genes reported by Elyada et al as upregulated in the 
double (p53 and Csnk1a1) knockout mice and involved in murine tumor invasiveness3. 
Two human genes, mainly PLAT (plasminogen activator tissue) and PNLPRP1 (pancreatic 
lipase related protein 1) were significantly differently expressed between two groups 
of patients; the group with low CSKN1A1 expression and non functional p53 vs the 
remaining group (with functional p53 and high or low CSKN1A1 expression and non 
functional p53 and high CSNK1A1 expression). PLAT was upregulated in the latter group 






Log Rank p53 functional vs.  non functional p=0.009 
p53 functional N=29; p53 non functional N=28
Figure 3: Kaplan Meier plots for CSS according to p53 functionality.
Figure 4: Trends in expression of the three CSNK1A1 probes.
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Log Rank high vs. low CSKN1A1 expression p=0.38 
Low CSNK1A1 expression N=12; High expression N=16
Log Rank high vs. low CSNK1A1 expression p=0.007
Low CSNK1A1 expression N=15; High expression N=9
Figure 5: Kaplan Meier plots for CSS according to CSNK1A1 expression stratified on 





p53+ & CSNK1A1+/- and p53- & CSNK1A1 + N=37  
p53- CSNK1A1- N=15
Figure 6: Kaplan Meier for CSS according to p53 and CSNK1A1 combination variable.
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Variables HR 95% CI p value
p53 & CSNK1A1 status
   p53 - & CSNK1A1 + and p53+ & CSNKA1A +/-
   p53 - CSNK1A1 -
Referent
4.74 1.47 – 15.34 0.009*
Tumor stage
   I & II
   III
Referent
3.48 1.08 – 11.2 0.037*
Tumor location
   Right
   Left
Referent
0.92 0.32 – 2.67 0.58
Gender
   Male
   Female
0.92
Referent
0.32 – 2.97 0.88
MMR state
   MSS
   MSI
0.43
Referent
0.097 – 1.91 0.27
Table 4: Cox Proportional Hazards Model: multivariate survival analysis.






p53 is a transcription factor with important functions in cellular apoptosis, senescence, 
DNA damage repair, autophagy, aging and glycolysis 31-33. Therefore, it is a strategic 
target for inactivation in cancer cells and indeed it is found mutated in approximately 
50% of all tumors 4. However, the consequences of p53 inactivation in disease outcome 
in colon cancer remain controversial and a matter of discussion. Differences in the 
techniques used to assess p53 alterations (IHC or mutation analysis), together with the 
many possible ways of p53 inactivation (deletion and dominant negative, loss or gain 
of function mutations) play a part in the inconclusive results. We studied TP53 using 
several approaches; first we determined tumor ploidy and TP53 locus allelic state. 
Next, we assessed TP53 mutation state and protein expression by IHC. Integrating 
all these data we were able to reliably predict p53 functionality. The classification in 
functional and non functional p53 was ratified by the significant differences in target 
gene expression between these two groups. Known p53 targets such as CDKN1A and 
MDM2 were significantly higher expressed in the p53 functional group than in the 
non functional, corroborating p53 functional state. Thus, with this approach complete 
information over the gene was obtained allowing a more reliable classification than by 
mutation analysis or immunohistochemistry solely.
As it could be expected based on the functions of p53, tumors with a non functional 
p53 were highly aneuploid and had a poorer prognosis than patients with functional 
p53. 
We have also shown that p53 can indeed behave as a haploinsufficient tumor suppressor 
gene in humans as already seen in mice models 20. By the use of SNP array we access the 
allelic state of the p53 locus and by additionally assessing TP53 mutation state we were 
able to determine TP53 genotype accurately. In our cohort there were a few patients 
with LOH at the TP53 locus but without mutations in exons 5, 6, 7 and 8 and without 
positive immunostaining. Moreover, these patients had an almost diploid genome and 
all had a good disease outcome as compared with other patients. This finding supports 
what has been seen in mice, where p53 +/- mice did develop tumors but show a milder 
phenotype than p53-/- mice 20.
Recently, Csnk1a1 or CKIα expression has been implicated in colon cancer invasiveness 
and cell transformation in mice gut 3. CSNK1A1 is a serine/threonine kinase that 
phosphorylates β-catenin to target it for destruction 34. In a mouse model, ablation 
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of Csnk1a1 caused the accumulation of β-catenin in the cytoplasm and nucleus 
activating many Wnt target genes although no tumor formation was observed. Instead, 
senescence was induced in these cells pointing to a possible role in tumor inhibition of 
p53. Indeed, the authors found that inactivation of both Csnk1a1 and p53 rendered 
the cell malignant and rapidly invasive 3. Likewise, in the present cohort of patients, 
we have identified CSNK1A1 as a dramatic modifier of p53 effects on survival. High 
CSNK1A1 expression partly counteracts the negative effects of a non functional p53. 
Accordingly, low CSNK1A1 expression and non functional p53 was equal to a very poor 
prognosis with a median survival time of 3 years and a 5-year survival of only 35%, 
which is extremely poor for early stage disease. Furthermore, this negative effect on 
survival was independent of disease stage, gender, tumor location and mismatch repair 
state, as shown in the multivariate analysis. 
The exact mechanism behind this poor survival is unknown; Elyada et al showed that 
expression of certain genes was upregulated in the double knockout mice (p53-/- and 
Csnk1a1-/-) as compared with the only Csnk1a1-/- mice. Some of these genes were 
involved in loss of enterocyte polarity, tissue remodeling and cell motility; all functions 
likely to be involved in tumor invasiveness 3. In the present cohort of patients only 
two of the human homologues from the murine gene list proposed were differentially 
expressed, i.e. plasminogen activator tissue (PLAT) and pancreatic lipase related protein 
1 (PNLRP1) in tumors with impaired p53 function and low expression of CSNK1A1 versus 
the remaining tumors. The latter results might reflect differences between mouse and 
man. Moreover, the human comparison was not identical to the murine comparison 
by Elyada and co workers. Furthermore in contrast to the murine model, PLAT was 
upregulated in the group with at least one active gene (functional p53 with low or high 
CSNK1A1 expression and non functional p53 with high CSNK1A1 expression) and could 
therefore be associated with a better survival. In human, the increased expression 
of the plasminogen activator inhibitor was associated with the occurrence of distant 
metastasis in colon cancer 35, probably leading to decreased levels of PLAT which would 
corroborate our findings. To our knowledge, the role of PNLRP1 in tumor invasiveness 
and progression is so far unknown.
In conclusion, the combination of several approaches gives additional and accurate 
information on p53 status showing a detrimental effect on survival when p53 function 
is impaired. Nevertheless, gene interplay remains very important in tumor biology as it 





of TP53 in colon cancer. Loss of both genes confers an extremely poor prognosis to 
colon cancer patients.
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Abstract
Apart from its activating function in the MAPK transduction pathway, mutated BRAF 
has been recently implicated in mitochondrial oxidative phosphorylation, resistance 
to apoptosis, mitotic spindle alterations and aneuploidy. In colon cancer, V600E BRAF 
mutated tumors show different gene expression profile than KRAS and double wild 
type tumors. Moreover, the V600E BRAF mutation has also been associated with a 
poor prognosis. 
We aimed to investigate the genomic profile of BRAF V600E mutated microsatellite 
stable (MSS) colon cancer tumors and compare it with double wild type MSS tumors. 
For this purpose, thirty four patients with stage II and III colon cancer were selected for 
tumor cell flow sorting, DNA isolation of normal and tumor fractions and hybridization 
to the high density Affymetrix Oncoscan™ FFPE Express SNP array.
BRAF mutated tumors have a different genomic profile than double wild type tumors. 
Concretely, the BRAF mutated tumors show more frequently gain of chromosome 18p 







BRAF is a serine threonine kinase involved in the KRAS/ERK transduction pathway. 
Several mutations in the BRAF gene have been described; however the mutation 
causing the substitution of valine by glutamic acid at position 600 of the protein is the 
most frequent one, representing 95% of the BRAF mutations. In colon cancer the BRAF 
c.1799T>A, p.V600E mutation does not coexist with KRAS mutations. This observation 
together with the fact that these two proteins function in the same signaling pathway 
suggest possible overlapping functions of KRAS and BRAF. However, compared to 
KRAS mutated or double wild type tumors, the BRAF V600E mutated tumors show 
a different phenotype consisting in poor differentiation, microsatellite instability and 
proximal location in the colon. Moreover, the pattern of metastatic spread of BRAF 
mutated tumors seems to be different than that of non BRAF mutated tumors. Tumors 
with a BRAF mutation spread more frequently to the peritoneum, distant lymph nodes 
and less frequently to the lung regardless of the microsatellite status. Liver and central 
nervous system metastases rates did not differ between BRAF mutated and wild type1. 
The BRAF V600E mutation has been associated with poor prognosis in early stages of 
colon cancer, mainly in microsatellite stable (MSS) tumors 2-4 and with prognosis and no 
response to anti-EGFR therapy in metastatic colon cancer 5,6. Recently, a specific BRAF 
V600E gene expression signature in colon cancer has been described 7. This profile 
based on the expression of approximately 30 genes seemed to differ greatly from the 
KRAS mutation profile based on the expression of 90 genes and also from double wild 
type tumors. Based on this evidence, one could state that BRAF mutated tumors are 
indeed different entities as compared with KRAS mutated and double wild type tumors. 
Furthermore, oncogenic BRAF might have more functions than protein phosphorylation 
in signal transduction: the BRAF V600E mutant protein has also been implicated 
in dysregulation of apoptosis in colon cancer 8 and recently with mitotic spindle 
aberrations leading to chromosomal instability in melanoma cell lines. The transfection 
of melanoma cell lines with a construct containing BRAF V600E caused aberrant 
mitotic spindles, altered centrosomes and missegregation of chromosomes leading to 
aneuploidy. These mitotic spindle alterations were reversed by BRAF V600E inhibition 9. 
Moreover, in thyroid cancer BRAF V600E has been found to locate at the mitochondria, 
suggesting a possible role in apoptosis and oxidative phosphorylation 10.
We hypothesized that BRAF mutant colon cancers could have other genomic aberrations 
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than double wild type tumors and that these genomic aberrations could be responsible 
for the poor prognosis of these patients. In order to obtain the most reliable results, 
we purified the epithelial tumor fraction of double wild type and BRAF V600E mutated 
samples by flow cytometry, isolated DNA and performed a 300K SNP array. Our results 
show indeed different genomic signatures for BRAF mutant tumors as compared with 







Colon carcinoma tissue of 34 patients diagnosed at the PAMM laboratory for pathology 
in Eindhoven, the Netherlands were selected on the basis of microsatellite stability 
(MSS), BRAF V600E mutation status, and being wild type for KRAS at codons 12 and 
13 2.  Six patients had stage II disease whereas 28 had stage III. Twenty of the stage 
III patients (71%) had received adjuvant chemotherapy previously to tissue collection 
(two received 5-FU combined with oxaliplatin, whereas the rest received 5-FU/LV). All 
of the stage II patients and eight of the stage III were treated with surgery solely.
Half of the patients where double wild type for both BRAF and KRAS, while the other 
half had a BRAF V600E mutation. Variables like age, gender, T and N stage, tumor 
differentiation etc. were matched between the two groups. However, it was not 
possible to match tumor location because the presence of a BRAF V600E mutation 
correlates with tumor location on the right side of the colon. Also, the selected BRAF 
mutated samples had a worse disease outcome than no BRAF mutated samples. Follow 
up data were obtained from the available medical records.
Tissue preparation for multiparameter flow cytometry and sorting
Tissue preparation for flow cytometry was carried out as previously described with 
minor modifications 11. Tumor areas were selected by an experienced pathologist (IvL). 
Subsequently, 2 mm punches were taken and embedded in new blanco paraffin acceptor 
blocks. 60µM sections were then sliced, deparaffinised and rehydrated followed by heat 
induced antigen retrieval which was performed by warming the tissues for one hour 
at 80°C in 10mM sodium citrate (pH=6.0). Next, tissues were dissociated enzymatically 
with a mixture of collagenase and dispase and mechanically with the gentleMACS™ 
mechanical dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) until 
a cell suspension was obtained. Cells were then counted and primary antibodies 
added; mouse monoclonal AE1/AE3 (Millipore, Temecula, CA, USA) and MNF116 
(DAKO, Golstrup, Denmark) pankeratin and mouse monoclonal V9-2b against vimentin 
(antibodies for research applications, Gouda, the Netherlands) in 1:200, 1:100 and 1:50 
dilutions respectively. After overnight incubation, secondary antibodies were added, 
GaMIgG1-FITC and GaMIgG2b-APC both diluted 1:100 (Southern Biotech, Birmingham, 
Al, USA) followed by the DNA staining solution containing 10 µM propidium iodide 
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and 0,1% RNAse (Sigma-Aldrich, Zwijndrecht, the Netherlands). Cells were then sorted 
using the FACS ARIA I and the FACS ARIA SORP (BD Biosciences, San Jose, CA, USA) 
based on cellular vimentin, keratin expression and DNA content. 
DNA index (DI) defined as the ratio between the median G0/G1 keratin epithelial 
fraction and the median GO/G1 vimentin stromal fraction, was calculated using a remote 
link between Winlist 6.0 and ModFit 3.21. (Verity Software House) for each sample. 
Whenever, more than one keratin positive population was seen, it was independently 
sorted. DI was categorized as DI< 0.95 or DNA hypodiploid; DI=0.95 – 1.05 DNA near 
diploid; DI=1.06 – 1.4 DNA aneuploid and DI=1.41 – >1.95 DNA tri or tetraploid.
Harvested cells were centrifuged for 20 minutes at 13.000 rpm and kept at -80°C 
until DNA isolation. DNA was isolated after proteinase K digestion at 56°C overnight 
and purified with Nucleospin Tissue (Marcherey Nagel, Düren, Germany) following 
manufacturer’s instructions. DNA concentration was adjusted to 15 ng/µL according to 
picogreen® measurements.
High density SNP array OncoScan™ FFPE Express
Two samples (one tumor and one normal sample) were excluded from further analysis 
because of their poor DNA quality. Sixty-six samples (33 normal and 33 tumor samples) 
as well as their matched normal DNA were hybridized on the OncoScan™ FFPE Express 
(Affymetrix, Inc. Santa Clara, CA, USA). This array challenges 330000 SNP markers in the 
genome with an average markers spacing of 9119 bp. After the hybridization, sixteen 
double wild type samples and fifteen BRAF V600E mutated samples were available for 
analysis.
Statistical Analysis
In order to identify genomic regions with identical copy number, normalized allele 
intensities (as provided by Affymetrix) were segmented using the circular binary 
segmentation12.
After all samples have been segmented the overlapping segments across all samples 
were reduced to unique segments. For both whole genome and chromosomal arms, we 
used the global test to evaluate for presence of differences in copy number between 
BRAF mutated and double wild type13 . Differences between groups were accepted as 





Association between categorical variables was calculated by the χ2 Fischer Exact Test 
with SPSS v16 for Windows (SPSS, Inc. Chicago, Il. USA).
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Results
The clinical and epidemiological characteristics of the thirty-four patients are shown in 
table 1. As previously stated, there were no differences in the distribution of the clinical 
and epidemiological variables between the two groups except for tumor location and 
disease outcome.
DNA index was determined for each sample during FACS. Six samples (18%) had 
two keratin positive populations with different DNA indexes. The distribution of the 
different DNA indexes according to the mutation status is shown in figure 1. Globally, 
the median DNA index was 1.54 (0.94 – 1.97). DI categories were made as follows, 9% 
DNA hypodiploid (DI<0.95); 12% DNA near diploid (≥0.95 – 1.05); 18% DNA aneuploid 
(1.06 – 1.40); 62% DNA triploid/tetraploid (1.41 - >1.95). There were no significant 
associations between number of cell populations and DI with BRAF mutational status 
or with other clinical or epidemiological variables. 
After hybridization on the array, data was available from sixteen double wild type 
samples and fifteen BRAF mutated samples which represent a success rate of 90%.
Previously described genomic aberrations in colon cancer are seen in both groups 
without significant differences14-20 (figure 2, table 2).
On average BRAF mutated samples showed a higher number of genomic fragments  than 
double wild type samples, although no statistical significance was reached possible due 
to the low sample size. Nevertheless, the copy number profile is significantly different 
between BRAF V600E mutated and double wild type samples (p=0.002). In order to 
investigate which chromosomal arm contribute to the overall difference between the 
two groups of patients, it was observed that alterations in chromosomes 3p, 6p and 
6q, 18p and 20q were significantly different between both groups (see table 3). When 
compared with the double wild type group, chromosome losses were more frequently 
in the BRAF mutated group in 3p, 6p, and 6q (p=0.03, p=0.03 and p=0.02), while 
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Follow up status *
   No Evidence of Disease
   Alive With Disease
   Dead of Disease













Median age (range) 66 (44 – 79) 64 (44 - 79) 69 (46 - 77)
Median Follow up (range) 44 (0 – 96) 61 (22 – 96) 35 (0 – 93)
Table 1: Patient’s clinicopathological characteristics.
* Statistically significant p=0.017
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Figure 1: DNA index according to BRAF mutation status.
 Chromosome arms p-value
CN chr. 1p loss 0.65
CN chr.1q loss 0.9
CN chr. 8p loss 0.8
CN chr. 8q gain 0.52
CN chr.13 gain 0.13
CN chr. 17p loss 0.73
CN chr.18q loss 0.17
CN chr.22 loss 0.27
Table 2: Known genomic alterations in colon cancer. Differences between BRAF 





Figure 2: Genomic profile BRAF V600E mutated group (upper panel) vs. double wild 
type group (lower panel). Upper row represents chromosome numbers; second row  
gene density according to the RefSeq database; third row, the mean gains and losses 
for the BRAF V600E group, as the row between panels for the double wild type group. 
Genomic gains are indicated in red, losses in blue, with a summarizing scheme above 
each pannel. The genomic profile of the BRAF V600E mutated tumors group differs 
significantly from that of the double wild type tumors. 
Table 3: Specific genomic regions differently affected between double wild type and 
BRAF V600E mutated samples. 
Chromosome arms p-value Corrected p-value
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Discussion
Based on our results we can conclude that BRAF mutated colon cancer tumors have a 
distinctive genomic profile as compared with double wild type colon cancer tumors. 
Focal regions on chromosome 18p, 20q, 3p, 6p and 6q were differently affected in the 
BRAF mutated samples as compared with the double wild type samples. Furthermore, 
BRAF mutated tumors seemed to be more aberrant than double wild type tumors as 
the number of genomic fragments causing a so called “scattered genomic pattern” was 
greater than in double wild type specimens albeit not yet statistically significant. 
The scattered pattern could be due to the induction by oncogenic BRAF of pleiotropic 
spindle abnormalities leading to chromosome missegregation and aneuploidy as 
described by Cui et al9. As stated by the authors, the abnormalities caused by oncogenic 
BRAF are expected to occur at random explaining the scattered pattern found in this 
study. At the same time, this mechanism could not be responsible for the specific 
chromosomal alterations in chr.18p, chr.20q, chr.3p, chr.6p and chr.6q seen in the BRAF 
mutated group; raising the question of what could be the mechanism behind these 
alterations. Does BRAF play a causative role on it, facilitating selection of mutated 
clones and hence a more aggressive disease history or does it just constitute together 
with the other alterations a signature identifying a type of colon cancer with a very 
aggressive course?
Loss of 6q has been independently associated with the development of colon cancer 
and with a more aggressive form of the disease. To our knowledge there is no direct 
association described between chr.3p loss and colon cancer; however, many genes are 
affected by the loss of this region like for instance FOXP1. Overexpression of FOXP1 has 
been associated with a better disease outcome in breast cancer patients21. Possibly, 
loss of this gene as seen in the BRAF V600E mutant group might explain a poorer 
prognosis, although this last point remains to be proven. 
To our knowledge there are no reports over the other alterations and prognosis or 
BRAF.
In conclusion, in this study we show for the first time that BRAF V600E mutated 
and double wild type colon tumors show subtle differences at the genomic level. In 
general, BRAF mutated tumors have a different genomic profile than double wild type 
tumors. Moreover, these tumors show different focal and regional alterations, with 





genes involved in cancer formation or progression which are probably not caused by 
BRAF V600E itself. Whether these specific focal aberrations are caused by BRAF V600E 
directly or whether they constitute together with BRAF V600E itself a specific genomic 
profile of highly aggressive tumors remains unanswered and subject of future research.
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Abstract
Although, direct sequencing is the gold standard for KRAS mutation detection in routine 
diagnostics, it remains laborious, time consuming and not very sensitive.
Our objective was to evaluate SNaPshot and the KRAS StripAssay™ as alternatives to 
sequencing for KRAS mutation detection in daily practice.
KRAS exon 2 specific PCR followed by sequencing or by a SNaPshot reaction was 
performed. For the StripAssay™, a mutant enriched PCR was followed by hybridization 
to KRAS specific probes bound to a nitrocellulose strip. To test sensitivities, dilution 
series of mutated DNA in wild type DNA were made. Additionally, direct sequencing 
and SNaPshot were evaluated in 296 colon cancer samples. 
Detection limits of direct sequencing, SNaPshot and StripAssay™ were 20%, 10% 
and 1% tumor cells, respectively. Direct sequencing and SNaPshot can detect all 12 
mutations in KRAS codons 12 and 13, whereas the StripAssay™ detects ten of the most 
frequent ones. Workload and time to results are comparable for SNaPshot and direct 
sequencing. SNaPshot is flexible and easy to multiplex. The StripAssay ™ is less time 
consuming for daily laboratory practice.
SNaPshot is more flexible and slightly more sensitive than direct sequencing. The 
clinical evaluation showed comparable performances between direct sequencing and 
SNaPshot. The StripAssay™ is rapid and an extremely sensitive assay which could be 
considered when few tumor cells are available. However, found mutants should be 






Since the introduction of targeted therapy against the epidermal growth factor 
receptor (EGFR) for the treatment of metastatic colorectal cancer, mutation detection 
in downstream effector molecules like KRAS has become clearly more important in 
clinical practice. It has been well reported in literature that patients harbouring 
mutations in these molecules will not benefit from anti-EGFR treatment1, 2. Several 
mutations have been described in the KRAS gene, impairing response to anti-EGFR 
therapy. These mutations occur most frequently (97%) in codons 12 and 13 of exon 
2 (the first coding exon); less common (3%) are the mutations in codons 59 and 61 in 
exon 33. The clinical value of these latter mutations is still unknown. KRAS mutations 
occur early in colorectal carcinogenesis and are present in 30 up to 40% of colorectal 
carcinoma cases, independently of disease stage4. 
Recently, the American Society of Clinical Oncology (ASCO) has issued the 
recommendation to test for KRAS mutations in all patients with metastatic colorectal 
cancer before treatment with cetuximab5. Moreover, in Europe KRAS mutation analysis 
in stage II and III colon cancer has been recommended by an expert panel6. Thus, KRAS 
mutation detection plays an important role in colon cancer therapy decision making 
and could very well become one of the most frequently performed tests in diagnostic 
pathology laboratories in the future. 
Accurate mutation detection depends on several factors, including available tissue, 
DNA quality, DNA input and tumor cell percentage. All are important issues in limiting 
assay performance and sensitivity. The majority of assays in clinical practice are 
performed on formalin fixed paraffin embedded (FFPE) resection material. DNA from 
FFPE material is often of poor quality, impairing the performance of existing assays. 
Furthermore, DNA input can be a problem when little tissue is available as in needle 
biopsies. In addition, small numbers of tumor cells in a background of stromal cells can 
sometimes be challenging for accurate mutation detection as in the case of radio- and/
or chemotherapy pre-treated tumor specimens.
When choosing an assay for routine diagnostics, additional factors such as workload, 
time to results, hands-on time, dedicated equipment, costs, assay flexibility and 
robustness of a technique need to be addressed as well. Assay flexibility enables 
multiplexing resulting in mutation detection on several hotspots or genes at the same 
time, saving diagnostic time and DNA input. Assay robustness or reproducibility is 
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mandatory to implement it in high throughput routine diagnostics. Finally, additional 
factors influencing technique choice are the capacity, equipment present and available 
expertise in a laboratory.
In most of the pathology laboratories direct sequencing, i.e. PCR followed by 
dideoxy sequencing, is considered as the gold standard for KRAS mutation detection. 
However, this technique is not only laborious and time consuming, sensitivity plays 
an important role. In order to reliably test a sample at least 20 to 30% of tumor cells 
are needed. To date, there are several alternative assays available for (KRAS) mutation 
detection, including home brew assays like high resolution melting curve analysis 
(HRM)7, pyrosequencing8, single nucleotide primer extension assay9 allele specific 
real time PCR10 and commercially available assays like reverse hybridization test KRAS 
StripAssay™ (Vienna labs, Vienna, Austria)11 and real time PCR based TheraScreen™ 
(Roche Diagnostics, Almere, the Netherlands); all these assays greatly differ in sensitivity, 
specificity, DNA input, time to results, hands-on time, flexibility, workload and costs. 
The single nucleotide primer extension (SNaPshot) assay is a home brew, flexible assay, 
which might be easily extendable to other biomarkers, whereas from the commercially 
available assays the KRAS StripAssay™ claims to be fast and very sensitive. 
Therefore in this study we aimed to evaluate the SNaPshot and reverse hybridization 
StripAssay™ in comparison to direct sequencing for KRAS mutation detection in colon 
cancer. Several parameters important for implementation in a pathology laboratory 
such as sensitivity, specificity, workload, time to results, hands-on time, flexibility, DNA 







In order to test the workload, time to results, hands-on time, costs, flexibility and 
specificity, 296 colon cancer samples available in the archives of the laboratory for 
pathology PAMM Eindhoven in the south of the Netherlands were used. Areas 
with sufficient tumor cell percentage were selected from diagnostic HE slides by an 
experienced pathologist. Percentages of tumor cells varied from 20 to 90%. These 
areas were macrodissected after tumor cell content check in new sandwich HE slides. 
Tissue input for DNA isolation was approximately 0.5 cm2. 
DNA was isolated by proteinase K digestion at 56°C overnight followed by purification 
with the HPTTP kit following manufacturer’s instructions (Roche, Almere, the 
Netherlands). 
To test the sensitivity of each assay, four different dilution series of mutant tumor DNA 
in wild type DNA were made. Five different mutations (c.34G>T; p.Gly12Cys, c.38G>A; 
p.Gly13Asp, c.35G>A; p.Gly12Val, c.35G>A; p.Gly12Asp and c.34G>C; p.Gly12Arg) were 
represented in these series. Tumor cell percentages of 80, 40, 20, 10, 5 and 1% were 
tested with the three assays.
To investigate possible false positivity of the StripAssay™, additional samples were 
tested. DNAs from eighteen samples containing a minimum of 75% tumor cells and 
previously diagnosed as wild type by direct sequencing and SNaPshot and two normal 
colonic mucosa samples were isolated following the same protocol as previously 
described. Subsequently, PNA PCR clamping was performed. The obtained PCR 
products were hybridized to the StripAssay™ strip and sequenced.
KRAS PCR and dideoxy sequencing
PCR for the amplification of codons 12 and 13 in exon 2 was performed using 
the primers described elsewhere12. The expected product length was 170 bp. 
Subsequently, 206 PCR products were purified using the QIAquick gel extraction kit 
(Qiagen, Venlo, the Netherlands) following manufacturer’s instructions whereas 90 
PCR products were purified by the enzymatic reaction with ExoSapIT (USB Co, Staufen, 
Germany). The change in purification method was due to the less laborious character 
of enzymatic purification, not affecting quality of sequence results. Purified products 
were then sequenced using the same primers as for the amplification and Big Dye 
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Terminator v1.1 cycle sequence kit (Applied Biosystems, Nieuwerkerk aan de IJssel, 
the Netherlands). Sequencing products were separated in the ABI 3100 and analyzed 
using the Sequencing Analysis 5.3.1 software (Applied Biosystems, Nieuwerkerk aan de 
IJssel, the Netherlands). Based on the fact that in our laboratory we have not found any 
discrepancy between KRAS mutation detection in wild type KRAS cases by sequencing 
with the forward or the reverse primer and to decrease workload, reactions were 
initially performed with the reverse primer. When a mutation was found, this was 
confirmed in a newly generated PCR product using the forward primer. 
KRAS SNaPshot
PCR was performed using the same primer pair as for dideoxy sequencing12. 
Subsequently, products were purified with ExoSapIT (USB, Staufen, Germany). Next the 
single nucleotide primer extension reaction was performed as previously described 9 
by adding four different oligonucleotides for each mutation hotspot and allowing the 
addition of a specific ddNTP differently labelled (figure 1). The following oligonucleotides 
were used 5’AAC TTG TGG TAG TTG GAG CT3’ 5’N10ACT TGT GGT AGT TGG AGC TG 3’ 
5’N20TTG TGG TAG TTG GAG CTG GT 3’ and 5’N30 TGT GGT AGT TGG AGC TGG TG3’. 
Primer extension reaction was performed according to manufacturer’s instructions 
using the ABI PRISM SNaPshot™ multiplex kit (Applied Biosystems, Nieuwerkerk aan 
de IJssel, the Netherlands). Finally, products were run by capillary electrophoresis in 
an ABI 3100 and analyzed using the Genemapper v4.0 software (Applied Biosystems, 
Nieuwerkerk aan de IJssel, the Netherlands).
 ddATP 
T40 
A/G 46 46.5 









Figure 1: Schematic representation of the SNaP shot technique. 
The primers have a certain length and end one nucleotide before the mutation. Subsequently, 
one fluorochrome labelled dideoxynucleotide is added. Using capillary electrophoresis products 
are separated according to size. Depending on the nucleotide build in after primer extension 






The KRAS StripAssay™ as recently described by Ausch et al11 was performed according 
to manufacturer’s instructions (Vienna Labs, Vienna, Austria). Briefly summarized, 
a PCR enriched for mutant KRAS alleles is performed. This PCR is based on wild 
type sequence clamping with a specific PNA oligonucleotide, allowing preferred 
amplification of the mutant sequence13; 14. Subsequently, PCR products are hybridized 
to a nitrocellulose strip containing specific probes for the different mutations (figure 2). 
After hybridization, the test strip is washed, blocked and color is developed11.
Figure 2: KRAS mutations present on StripAssay™.
1 Wild type; 2 p.Gly12Ala; 3 p.Gly12Arg; 4 p.Gly12Asp; 5 p.Gly12Cys; 6 p.Gly12Ser; 7 p.Gly12Val; 8 
p.Gly13Asp; 9 p.Gly13Cys
p.Gly12Ile and p.Gly12Leu are not present in our series but present on the StripAssay™. 
p.Gly13Val and p.Gly13Arg are not present on the StripAssay™.
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Results
Technical validation: Sensitivity, specificity and performance.
Sensitivity
The sensitivity of three techniques, i.e. direct sequencing, SNaPshot and StripAssay™ 
was determined for KRAS mutation detection using different dilution series of mutated 
DNA with wild type DNA ranging from 80% to 10% or to 1% tumor cells. Different 
mutations, i.e. c.34G>C; p.Gly12Arg, c.34G>T; p.Gly12Cys, c.38G>A; p.Gly13Asp, 
c.35G>T; p.Gly12Val and c.35G>A; p.Gly12Asp were used for the dilution series.
A reproducible and reliable mutation detection limit of 20% tumor cell percentage 
was obtained for direct sequencing (see table 1 and figure 3). As shown in table 1, 
in two samples, mutation detection by direct sequencing was positive with only 10% 
tumor cells. However, reproducible results were not possible with less than 20%. The 
sensitivity of the SNaPshot assay was 10% tumor cells in the sample (see table 1, figure 
3 and 4). Finally, the StripAssay™ appeared to be the most sensitive technique with a 
mutation detection limit of 1% tumor cells (table 1 and figure 4).
To investigate possible false positivity of the StripAssay™, additional samples, 
known to be wild type KRAS by direct sequencing and SNaPshot were tested by the 
StripAssay™ and sequencing of the clamped PCR product. Two conflicting results were 
found. Mutations were seen only by sequencing but products did not hybridize to the 
nitrocellulose strip. The mutations found were c.34G>A; p.Gly12Ser and c.39C>A with 
no aminoacid substitution. These samples were tested again and no mutants were 
found, neither with the StripAssay™ nor by direct sequencing.
Specificity 
Previously tested samples with known mutations were used to check specificity of the 
different techniques. Although, c.37G>C; p.Gly13Arg, c.37G>A; p.Gly13Ser and c.38G>C; 
p.Gly13Ala were not seen in our samples, we believe that they are detectable with 
direct sequencing and SNaPshot just like the other nine mutations in codons 12 and 13 
which were detected by both sequencing and SNaPshot. Of the mutations present in 
our series, the StripAssay™ failed to detect the c.38G>T; p.Gly13Val mutation because 
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Performance
Workload, time to results, hands-on time, flexibility, DNA input and costs were 
compared for the different techniques used and are summarized in table 2. The 
workload and time to results are similar for direct sequencing and SNaPshot. For both 
techniques it involves, PCR, PCR product purification, either extension or sequencing 
reaction, second purification step and subsequent run by capillary electrophoresis. 
The hands-on time post DNA isolation for both techniques is approximately two hours 
work. The time to results, post DNA extraction, is approximately two days for direct 
sequencing and one and a half days for SNaPshot around respectively. When using the 
StripAssay™, hands-on time is about one and a half hours and time to results post DNA 
extraction, can be half a working day. 
DNA input is similar in all three assays tested. Generally, the isolation of DNA from 1 
cm2 tissue is enough to perform several reactions.
Costs for reagents vary from 5 euros per sample for direct sequencing and SNaPshot 
assay to 80 euros per sample for the StripAssay™ in the Netherlands. However, labor is 
not included in these prices nor the costs of dedicated laboratory equipment necessary 
to carry out sequencing and SNaPshot assay.
SNaPshot is the most flexible of the three techniques facilitating the use of multiplex 
reactions. Direct sequencing does not allow the use of multiplex PCR. The StripAssay™ 
is a commercial assay; its flexibility is poor and depends on the manufacturer’s choice 
in further development. 
Clinical validation
KRAS mutations were found in 107 of the 296 colon cancer samples tested, 36% of 
the study group. Table 3 shows the frequencies of the different mutations found in 
these samples. On average, mutation frequencies were in agreement with frequencies 
published in the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/ 
viewed June 30th, 2010). These results were identical with direct sequencing and with 
single nucleotide primer extension.
The c.38G>T; p.Gly13Val mutation which is not available in the StripAssay™ was found 





Table 2: Evaluation of performance of the three techniques.
Direct sequencing SNaP shot StripAssay™
Workload Laborious Laborious Time sparing
Result interpretation Time consuming Easy Easy
Sensitivity 20% 10% 1%
Quantification semiquantitative semiquantitative Non quantitative
Flexibility No Yes No
Costs 4 euro 4 euro 85 euro*
Assay hands-on time 2 hours 2 hours 1.5 hours
Time to results 2 working days 1,5 working days 1 working day
Special equipment Sequence facilities Capillary electrophoresis Not required















c.35 G>T c12 GGT>GTT p.Gly12Val 19/107 (18) 22.9
c.35 G>A c12 GGT>GAT p.Gly12Asp 33/107 (31) 35
c.35 G>C c12 GGT>GCT p.Gly 12Ala 9/107 (8) 6.5
c.34 G>T c12 GGT>TGT p.Gly12Cys 9/107 (8) 9
c.34 G>A c12 GGT>AGT p.Gly12Ser 6/107 (6) 6.5
c.34 G>C c12 GGT>CGT p.Gly12Arg 3/107 (3) 1.3
c.38G>A c13 GGC>GAC p.Gly13Asp 26/107 (24) 17.6
c.38 G>T c13 GGC>GTC p.Gly13Val 1/107 (1) 0.1
c.37 G>T c13 GGC>TGC p.Gly13Cys 1/107 (1) 0.5
c.37 G>C c13 GGC>CGC p.Gly13Arg 0 0.3
c.37 G>A c13 GGC>AGC p.Gly13Ser 0 0.15
c.38G>C c13 GGC>GCC p.Gly13Ala 0 0.1
Table 3: KRAS mutation frequencies according to COSMIC database and in colon 
cancer samples.
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Discussion
The recent advices from the ASCO and a European expert panel to perform KRAS 
mutation detection prior to therapy with cetuximab in metastatic colorectal cancer 5 and 
in stage II and III colon cancer 6, respectively, has made the need for a sensitive, flexible, 
fast and easy to implement in daily practice assay urgent. Therefore, we compared 
three currently available techniques for implementation in routine diagnostics. The 
gold standard direct sequencing was compared to "in house" developed SNaPshot and 
partly to the commercially available StripAssay™.
Several parameters were accounted for including sensitivity, specificity, workload, 
time to results, hands-on time, flexibility and costs. However, the choice of a technique 
also depends on other variables such as equipment, expertise and personnel available 
in a molecular diagnostics laboratory.
In this study, SNaPshot showed to be a very sensitive technique which performed 
well with paraffin embedded tissues. Without any mutant DNA enrichment strategy 
before the KRAS specific PCR, we obtained reproducible and robust results in the entire 
cohort of patients tested. All mutations previously obtained with direct sequencing 
were confirmed with the SNaPShot technique and frequencies agreed with the COSMIC 
database (table 3). The fully consistent results between SNaPshot and direct sequencing 
can be explained by the selection of samples. All samples must contain more than 30% 
tumor cells, which in turn is higher than the detection threshold for both techniques 
10 and 20% respectively. Moreover, both techniques compared are performed using 
different PCR products, but the same DNA extracted from clinical specimens. We know 
that DNA extraction is a crucial factor for test reproducibility and subsequent possible 
differences in sensitivity. Workflow is similar to direct sequencing, hands-on time 
post DNA extraction is approximately two hours whereas time to results after DNA 
isolation is approximately one and a half working days. In our opinion, the SNaPshot 
assay has two main advantages when compared to direct sequencing. First, SNaPshot 
was more sensitive than dideoxy sequencing being able to detect mutations in samples 
containing 10% tumor cells in a background of wild type cells. Second, this technique is 
very flexible. It is easily extendible to other KRAS mutations and to mutations in other 
genes like for instance the BRAF V600E mutation. This characteristic can be important 
in the future. With the introduction of more targeted therapies it seems likely that gene 





can save diagnostic time and material input, besides reducing costs 15. However, primer 
design can be complicated and the use of multiplex reactions could affect sensitivity 
and therefore this issue should be addressed before implementing it in daily practice. 
In our hands, the most sensitive assay was the StripAssay™ based on mutant enriched 
PCR followed by reverse hybridization. The mutant enriched PCR is based on the 
clamping of the wild type sequence by PNA nucleotides therefore, only mutant DNA 
template is amplified. With this technique mutations were detected in samples 
containing as little as 1% tumor cells in a wild type background. These results are in 
agreement with previous reports using cell lines 11 where the same sensitivity was 
found for mutation detection. 
Although the hybridization to a specific probe after PCR amplification minimizes the 
risk of false positive results, one drawback of PNA PCR clamping can be false positivity 
due to Taq polymerase errors under the clamp depending on the amount of DNA 
template 16; 17. Thus, one should be aware of the fact that false positivity is a real 
concern when using techniques based on PNA PCR clamping. However, in our case, it is 
difficult to assess whether the false positivity was introduced during the PCR or during 
sequencing. The fact that clamped PCR products did no hybridize to the StripAssay™ but 
were found after sequencing, indicates that at least in one sample the error occurred 
during sequencing. Nevertheless, to minimize the risk of false positivity introduced by 
Taq polymerase errors, assays should be performed in duplicate and manufacturer’s 
instructions concerning DNA input, should be strictly followed. The latter, might be a 
difficult issue when using FFPE, since measurement of DNA amount is often unreliable.
Furthermore, such a sensitive technique could detect small subpopulations of tumor 
cells carrying mutant alleles within a majority of wild type tumor cells. Although 
KRAS mutation is generally accepted as an early event in colon carcinogenesis 4, 
tumor heterogeneity is a known feature 18. Baldus et al 18 have recently reported 
that mutations are differentially present in different areas of the tumor as well as 
in positive lymphnodes and metastasis. The clinical relevance of this finding is not 
fully understood, but it could greatly contribute to difficult therapy decision making. 
Mutated clones could be preferentially detected with the StripAssay™, while remaining 
undetectable with standard techniques such as direct sequencing and SNaPshot, even 
when sufficient tumor cells are present.
Thus, the high sensitivity of the StripAssay™ could be its biggest caveat and one 
should be very cautious when carrying out such a sensitive assay. It might well be 
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that even more expertise, more restricted laboratory discipline and special additional 
precautions are necessary to circumvent false positivity due to sample contamination. 
Furthermore, it is strongly recommended to confirm StripAssay™ positive samples by 
either a new StripAssay™ or another assay with a similar analytical sensitivity.
The workflow of the StripAssay™ is easy, the hands-on time is approximately one and 
a half hours and time to results after DNA isolation is half working day. This assay does 
not require any dedicated equipment. Thus, results can be obtained within one working 
day, halving diagnostic time. The price of the StripAssay™ currently commercialized by 
Vienna Labs (Vienna Labs, Vienna, Austria) is not competing with dideoxy sequencing 
or the SNaPshot assay in the Netherlands. The costs of mutation detection per sample 
with the StripAssay™ are approximately 20 fold higher than using direct sequencing 
or SNaPshot assay; however, labour costs are not included, dedicated equipment is 
not needed and finally, investment is not necessary for assay development, validation 
and quality control of reagents. Moreover, the StripAssay™ can be performed in all 
laboratories without dedicated equipment, whereas for direct sequencing and the 
SNaPshot technique a sequence capacity or a capillary electrophoresis machine are 
mandatory. 
Such low detection thresholds are not necessary in colon cancer molecular diagnostics. 
In general colon cancer samples contain more than 20% tumor cells. Nevertheless, 
for other tumor types such as neoadjuvantly treated rectal cancer without available 
biopsies and for lung cancer biopsies and cytology, high sensitivity is an important 
issue and sensitive techniques like the StripAssay™ might be clinically valuable. 
Other available techniques for KRAS mutation detection can also reduce workload, 
prices, time to results and sensitivity. HRM is recently described as a good alternative 
screening method 7. It is rapid, sensitive and accurate 19. By screening all samples 
with HRM, only aberrant samples need to be further analyzed to determine the 
underlying mutation, thereby decreasing sequencing workload. However, costs might 
increase, when no dedicated technology for HRM is present and must be additionally 
bought. Pyrosequencing is a sensitive, rapid and less laborious technique that can 
be a good alternative to direct sequencing. An advantage of pyrosequencing is that 
it is a quantitative assay which does not need PCR product manipulation diminishing 
contamination risk 8. Finally, real time allelic discrimination could also be a good 
alternative for direct sequencing because of the rapidity and high sensitivity of the 





probes lead to higher DNA input and a high risk of decreased specificity due to cross 
reactivity of the different probes 10.
When considering all aspects, we conclude that for colon cancer diagnostics, in which, 
sensitivity is generally not an issue and when capillary electrophoresis facilities are 
already available, SNaPshot can be as valuable as direct sequencing. Workflow, time to 
results, hands-on time and costs do not vary much between both techniques. However, 
the multiplex possibilities of the SNaPshot can reduce DNA input, costs and workload. 
Thus SNaPshot is a good alternative for direct sequencing for KRAS mutation detection 
in colon cancer patients in daily diagnostic practice. However, when sensitivity is an 
important issue such as in the case of lung cytology samples, or for small laboratories 
without dedicated equipment, highly sensitive techniques like the StripAssay™ should 
be considered due to its high sensitivity, rapidity and ease to perform. Nevertheless, 
one should be aware of the false positivity risks of such a technique and perform assays 
in duplicate to avoid false positives.
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Concluding remarks and future perspectives
The survival rates of patients with metastatic colorectal cancer have improved 
significantly due to the recent introduction of novel therapies. Moreover, the use of 
cetuximab, panitumumab and bevacizumab has accelerated the implementation of 
molecular testing in colon cancer diagnostics. Indeed, KRAS mutation detection in stage 
IV colorectal cancer has become standard practice in many pathology laboratories and 
other markers like BRAF V600E and PIK3CA will probably follow in the near future.
However, molecular characterization is currently used only in stage IV disease and not 
in earlier disease stages. Therefore, stage II and III are less well characterized at the 
molecular level, forming a rather heterogeneous disease group. Several parameters 
such as tumor localization, mismatch repair (MMR) status or tumor histology influence 
clinical behavior but are often not taken into account when defining clinical subsets.
Hence, this intertumor heterogeneity, together with intratumor heterogeneity and 
tumor plasticity are probably reasons for the discrete improvements in survival rates 
in these stages1 and the somewhat disappointing results of some of these novel clinical 
trials of the last decade2-4.
In stage II and III colon cancer, the identification of patients at risk of relapse, due to 
therapy resistance or to tumor intrinsic aggressiveness, is needed in order to improve 
disease management and outcome. Therefore, the main focus of this thesis was to 
identify molecular prognostic and predictive markers of response to therapy in stage 
II and III sporadic colon cancer. Predictive markers can identify patients who are not 
likely to respond to a certain chemotherapeutic drug, helping to decrease unnecessary 
exposure to that particular drug and thus toxicity. On the other hand, prognostic 
markers will identify patients with a poor natural history of their disease who will 
probably benefit from adjuvant chemotherapy or even from a more aggressive form of 




Pharmacogenetics & Predictive Markers
Since the mid-nineties the therapy guidelines for colon cancer management recommend 
the use of adjuvant chemotherapy after curative intended surgery for all patients with 
stage III colon cancer. This recommendation improved colon cancer patients’ survival. 
Risk of cancer related death in stage III patients was reduced in 29% (CI 13-42%) with 
5-FU monotherapy5. Combination of 5-FU with oxaliplatin, administered since 2005, 
reduced the risk of cancer related death with another 20%6. Despite this significant 
improvement in patient survival, a large percentage of patients apparently still do not 
experience any benefit from the treatment. 
We studied eight polymorphisms in genes coding for proteins involved in the 
metabolism of 5-FU and oxaliplatin such as the thymidylate synthase (TYMS), 
thymidine phosphorilase (TYMP), dehydropyrimidine dehydroxilase (DYMP), orotate 
phosphoribosyltransferase (OPRT), glutathion S transferase Pi (GSTPI), excision repair 
cross complementing group 1 (ERCC1) and excision repair cross complementing group 2 
(ERCC2) genes in stage III sporadic colon cancer patients. None of the polymorphisms 
studied was found to be a reliable marker predictive of therapy response in stage III 
disease.
These markers have been extensively studied by us and others, not only at the DNA 
level and in colon cancer but also at expression level (mRNA and protein) and in other 
types of cancer. Their value as predictive markers remains elusive because of conflicting 
results7-71. However, research groups did find certain genotypes (alone or combined) of 
the cited genes predictive of therapy response in colon cancer patients or indicative of 
therapy toxicity7-9,12,23-25,37,71.
The contradictory and inconclusive results might be explained by the retrospective 
character of the majority of the studies and the diversity of molecular techniques used. 
Furthermore different SNPs and genotype combinations were tested. On top of this, 
the results of functional experiments assessing the effect of a certain SNP in protein 
function and expression turned out to be contradictory as well67,72. This all makes the 
biological interpretation of the results complicated and probably unreliable. Moreover, 
most of the studies examined a heterogeneous population of patients including 
different disease stages, and differently located cancers (left-, right-sided or rectum). 
All these factors might give rise to the different results. Finally, even studies reporting 
positive relations between certain genotypes and disease outcome or therapy toxicity, 
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advocate for validation in prospective trials or larger cohorts before implementation 
in clinical practice.
Therefore, based on the existing literature and our experience, we conclude that in 
order to discard or implement such genetic markers in clinical practice, two types of 
studies are mandatory. Firstly, functional studies reporting the effect of SNPs on gene 
expression, protein function etc. are essential to determine which SNPs are likely to 
be relevant in pharmacogenetics. Secondly well-designed association studies, within 
prospective clinical trials are needed. Prospective clinical trials fulfill several criteria 
like large cohorts of patients that are carefully documented and homogeneously 
treated. Indeed, this approach has been used for reporting associations between 
toxicity and SNPs10,73 but less frequently for therapy response51. Another possibility 
is a retrospective study with an exploratory and a validation cohort. However, to 
study therapy response and toxicity, patients should have been equally treated and 
clinical course should have been carefully documented. In case of an exploratory and 
a validation cohort these are frequently not equally treated because of differences in 
disease management depending on location and time of diagnosis. 
Tan et al recently published the results of a clinical trial with rectal carcinoma patients. 
These patients were randomized between standard 5-FU based chemoradiotherapy 
and alternative 5-FU combined with irinotecan chemoradiation, on the base of a TYMS 
genotype. The authors concluded that classification of patients based on their genotype 
and subsequent variation of the therapy was feasible and that therapy results improved 
with this pharmacogenetic approach74. The latter trial constitutes a first step towards 
the incorporation of molecular pharmacogenomic testing in personalizing therapies 
in early stages of colon cancer. However, it also raises the question whether there is 




Somatic Mutations and Prognostic Markers
Given the enormous expansion of targeted therapies and their price coming with it, 
prognostic/predictive markers are essential for accurate patient’s classification and 
disease management. In addition, the molecular classification of patients and their 
tumors will contribute to more homogeneous study groups increasing the probability 
of reliable results and improvements in colon cancer therapy.
Prognostic markers are useful for a more accurate classification of patients and can 
identify different prognostic subgroups as seen for the BRAF V600E mutation. The 
latter mutation not only identifies patients with a poor prognosis independently of 
disease stage and even MMR status, but it also seems to characterize a type of tumor 
with an own genomic profile that is different than double wild type tumors. 
However, not all mutations have such a clear association with prognosis like BRAF 
V600E. We show in this thesis that the mutation in exon 20 of the PIK3CA gene has 
only prognostic value in stage III disease and not in stage II. Moreover, we also report 
that gene-gene interactions can affect the prognostic effects of certain makers. This 
is the case of TP53 inactivation which prognostic effects are greatly affected by the 
differential expression of the CSNK1A1 gene. Thus, although very complex, gene-gene 
interactions also need to be studied within the scope of prognostic markers research. 
In conclusion, molecular analysis of cancer cells can potentially aid to classify tumors 
more accurately and to manage patients accordingly. However, prognostic biomarkers 
need to be integrally analyzed to be able to explore genetic interactions and subtle 
molecular relations. Therefore, combined genetic, genomic, epigenetic and expression 
studies should be carried out. Likewise, basic functional research is essential to learn 
more about genetic interactions and to be able to correctly interpret data obtained 
from new techniques like SNP arrays or next generation DNA/RNA sequencing.
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Future Perspectives
To decrease colorectal cancer death in the future, two complementary approaches are 
necessary; on one hand, disease prevention and early diagnosis and on the other hand 
accurate disease classification should be established for personalized therapy.
 
Disease prevention 
By implementing screening programs for colorectal cancer, malignant tumor 
development can be prevented by excising premalignant polyps and cancer can be 
diagnosed at earlier stages like stage I/II when surgery is still curative. Indeed, several 
Western countries are implementing population based screening programs. The 
expectation, in The Netherlands, is to reduce colorectal cancer incidence and prevent 
mortality in 2400 patients per year out of the current 10 000 and therefore reduce 
treatment costs75.
Molecular disease classification
The second approach consists of the identification, validation and general 
implementation of molecular signatures identifying colon cancer subgroups. 
At this moment, all colon cancer patients with stage III and high risk stage II are 
treated equally without taking into account tumor molecular signatures. Recently, 
two colon cancer gene expression signatures associated with disease recurrence and 
poor prognosis in early stages have been published76,77. Although they have not been 
approved for clinical use yet, they represent one step forward in the use of molecular 
profiling in colon cancer classification. 
In the near future standard molecular stratification of patients and tumors should be 
able to define subgroups of patients leading to personalized treatment protocols.
A problem herewith is intratumor heterogeneity as well as tumor plasticity. Intratumor 
heterogeneity has been recognized for a long time now by surgeons, oncologists, 
pathologists and molecular biologists. Tumors may contain multiple clones that do not 
necessarily share the same molecular signatures or phenotypes. The different clones 
in a particular tumor evolve in time depending on tumor environmental influences like 
growth factors, hypoxia, inflammation, immune responses, stroma composition, et 
cetera. The study of these topics is technically challenging and difficult to solve and 




With the introduction of targeted therapies in cancer management tumor heterogeneity 
and plasticity have become even more important. These therapies target strategically 
chosen genes with activating mutations, based on the so-called oncogene addiction 
model. According to this model, cancer cells become dependent of certain activating 
mutations in key molecules in cell division, cell survival and signaling pathways 80. Cancer 
cells can circumvent the blocking of signaling pathway by acquiring novel mutations 
or switching to other pathways, thereby becoming resistant to a particular therapy. 
This adaptive capacity of the tumor is probably responsible for the relatively rapid 
relapses after treatment with targeted therapies seen in clinical practice. Moreover, it 
is currently unknown what is the minimum percentage of resistant or sensitive cells in 
order to consider a tumor resistant or sensitive for a given therapy 81. Thus, the clinical 
consequences of intratumor heterogeneity need to be further investigated as it is now 
technically more feasible79,82. 
Molecular pathology enabling the molecular classification of tumors and molecular 
biomarker determination in cancer diagnostics already plays an important role in 
daily clinical oncologic practice. However, put into perspective, a relatively very small 
proportion of molecular markers makes it eventually to daily clinical practice. In the 
nearby future  and derived from the use of new technologies, molecular diagnostics 
will probably play an essential role in tumor classification. Therefore, specific training 
of future pathologists in the field of molecular diagnostics is pivotal in order to ensure 
an effective interplay between oncologists, pathologists and molecular biologists, 
leading to patient tailored therapy. 
Besides, a vivid debate is taking place in the Netherlands about the implemetation of 
molecular diagnostics in pathology laboratories. At the present time, it is not legaly 
regulated which laboratory can carry out molecular diagnostics; both academic and 
non academic centers perform molecular diagnostics in pathology. However, the level 
of complexity is rapidly increasing, the development of new tests is expensive and 
specific expertise and knowledge are mandatory to interpret results. Thus, to ensure 
high quality, competitive prices and ongoing technological research and innovation, 
expertise and technologies should be, in our opinion centralized. 
Molecular prognostic markers or molecular tumor signatures will aid to classify colon 
cancer patients more accurately in order to improve disease management and patient 
outcome. These molecular signatures could be a complement to decision making 
tools for chemotherapy choice and even improve these tools. Molecular predictive 
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markers will help reduce cancer treatment toxicity of unnecessary therapy regimens. 
Collaborative studies to reach enough statistical power are mandatory to identify small 
subgroups of patients behaving differently clinically. Integral typing of these samples 
i.e. at a genetic, genomic, regulatory, epigenetic and expression level, mRNA, miRNA 
and protein levels, is recommended. Basic functional research is mandatory to make 
biological sense of data obtained from whole genome analyses. Finally, elucidating the 
role of intratumor heterogeneity and plasticity is an important challenge to understand 
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Colon carcinoom is het derde meest voorkomende type kanker in de Westerse wereld. 
In Nederland worden jaarlijks circa tienduizend patiënten gediagnosticeerd met colon 
kanker en ongeveer drie tot vier duizend patiënten overlijden aan deze ziekte. Vooral 
als de ziekte uitgezaaid is, is de prognose zeer slecht. In stadium II is de ziekte alleen 
aanwezig in de dikke darm, terwijl in stadium III,  de ziekte tot in de lymfeklieren 
is verspreid. In Nederland krijgen patiënten met stadium III ziekte, na chirurgie, 
chemotherapie om de kansen op overleving te vergroten. Stadium II patiënten krijgen 
alleen chemotherapie als ze hoog risico ziekte hebben. Hoog risico wordt gedeffinieerd 
als een slecht gedifferentieerde tumor,  diep invaderende tumor (T4), obstructie of 
perforatie van de darmwand of als minder dan 10 lymfklieren zijn onderzocht. De vijf 
jaar overleving varieert tussen 80% in stadium II tot 65% in stadium III. Deze cijfers 
zijn nogal teleurstellend voor een ziekte die alleen lokale tot regionale spreiding kent. 
De identificatie van markers van respons op chemotherapie en prognose zijn derhalve 
essentieel in deze twee stadia om patienten beter te kunnen classificeren en te 
behandelen, om de overlevingkansen te vergroten. 
Het onderzoek beschreven in dit proefschrift kent twee hoofddoelen; ten eerste 
het identificeren van moleculaire markers van chemotherapie respons in stadium III 
colon carcinoom, ook predictieve markers genoemd en ten tweede het bepalen van 
de invloed op overleving van een aantal genetische markers in stadium II en III colon 
carcinoom, in andere woorden prognostische markers. 
Hoofdstuk 2, 3 en 4 focussen op farmacogenetica, oftewel het bestuderen van DNA 
variatie in genen betrokken bij het metabolisme van chemotherapeutica en/of bij het 
herstel van de schade die deze geneesmiddelen veroorzaken. Voor de behandeling 
van colon carcinoom worden 5-Fluorouracil en oxaliplatin gebruikt. De effecten van 
DNA variatie in: Thymidylate synthase (TYMS), Thymidylate phosphorylase (TYMP), 
Dihydropyrimidine Dehydrogenase (DPYD), Ororate Phosphorybosyl Transferase 
(OPRT) op overleving is onderzocht in een cohort van patienten met stadium III colon 
carcinoma. Uit onze resultaten blijkt dat geen van de onderzochte DNA polymorfismen 
een effect heeft op overleving. Daarnaast is het effect op overleving, van variatie in 
DNA van genen betrokken in het herstel van schade veroorzaakt door oxaliplatin, zoals 
ERCC1, ERCC2 en in het metabolisme van oxaliplatin zoals GSTPI, onderzocht. Wederom 




In hoofdstuk 5, 6, 7 en 8 wordt de waarde van mutaties in bepaalde genen als 
prognostische markers onderzocht. Deze genen zijn allemaal betrokken in het ontstaan 
van colon kanker of bij de progressie van de ziekte.
Het blijkt dat de V600E BRAF mutatie een groep van tumoren identificeert met een zeer 
aggressief ziektebeloop. Daarnaast leveren we bewijs dat deze tumoren verschillen op 
genomisch niveau van tumoren zonder die mutatie. 
Tevens identificeren mutaties in het kinase domain van het PIK3CA gen een kleine 
subgroep van stadium III patiënten met een slechter beloop van de ziekte. Opvallend 
is dat dezelfde mutatie geen effecten in overleving blijkt te hebben in stadium II van 
de ziekte. Evenmin hebben mutaties in andere regio’s van het gen effect op overleving.
Verder wordt in dit proefschrift de rol van p53 als prognostische marker in colon 
carcinoom beschreven. Hieruit  blijkt een ander gen, namelijk caseine kinase 1 alpha 
subunit 1 (CSNK1A1), een belangrijke rol te spelen. Hoge expressie niveaus van het 
CSNK1A1 gen herstellen de negatieve effecten in overleving van een niet actief p53 
eiwit. Lage niveaus van CSNK1A1 en een niet actief p53 veroorzaken echter een zeer 
slechte overleving.
Concluderend, moleculaire pathologie voor de moleculaire classificatie van tumoren 
in het algemeen en colon carcinoom in het bijzonder zal in de nabije toekomst een 




There is an urgent need for predictive and prognostic markers in early stages colon 
carcinoma to be able to elucidate whether a patient is going to respond to therapy or 
not and also to be able to offer personalized treatment.
In this study, we aimed to identify predictive markers of therapy response in stage III 
disease and prognostic markers in stage II and III colon carcinoma.
In chapters 2, 3 and 4, the focus lies on pharmacogenomics with the aim to identify 
predictive markers. As colon cancer is treated with 5-Fluorouracil and oxaliplatin, the 
effect of DNA polymorphisms in genes involved in the metabolism of these drugs and in 
DNA damage repair caused by oxaliplatin on disease free survival was studied. 
Therefore, several polymorphisms in the following genes were tested; Thymidylate 
synthase (TYMS), Thymidylate phosphorylase (TYMP), Dihydropyrimidin Dehydrogenase 
(DPYD) and Ororate Phosphorybosyl Transferase (OPRT) together with Glutation S 
Transferase Pi (GSTPI), Excision Repair Cross-Complementation group one (ERCC1) and 
two (ERCC2). We concluded that none of the SNPs studied seemed to have effects on 
the disease free survival of stage III colon cancer patients. Thus, none of the studied 
SNPs was a reliable predictive marker of 5-FU or oxaliplatin response. 
In chapter 5, the focus is placed on the identification of molecular prognostic markers 
in stages II and III. The BRAF V600E mutation, mutations in codons 12 and 13 of KRAS 
and microsatellite instability were studied. BRAF V600E mutation conferred a poorer 
prognosis to colon cancer patients independently of microsatellite instability, KRAS 
mutational state, age, gender, T and N stage.
The value of mutations in other genes involved in signal transduction like PIK3CA is 
described in chapter 6. Mutations in the helical and in the kinase domain of this protein 
have different effects on survival. Moreover, while mutation in the kinase domain of 
PIK3CA in stage III disease conferred a very poor prognosis, the same mutation in stage 
II disease did not affect survival. Mutations in the helical domain did not affect survival 
in stage II nor in stage III disease.
In chapter 7, we try to unravel the role of p53 in prognosis of colon cancer. TP53 seems 
to be a haploinsufficient tumor suppressor gene implying that patients losing one 
allele and retaining the wild type allele are at risk of developing a tumor albeit with 
a favorable prognosis. Moreover, we also illustrate the importance of studying gene-




modifies greatly the effects of TP53 on survival. High CSKN1A1 expression counteracts 
the negative effects of a not functional p53 protein, whereas low CSNK1A1 expression 
decreases even more survival of patients with not functional p53.
In chapter eight, the genomic differences between BRAF mutant and double wild type 
tumors are described. BRAF mutated tumors seemed to be genomically more instable 
than double wild type tumors. These tumors also show specific genomic alterations 
that differ from double wild type tumors. 
Finally, in chapter nine, the challenges that diagnostic tests have to deal with before 
being implemented in daily clinical practice are described, taking KRAS mutation 




El adenocarcinoma de colon es el tercer tipo de cáncer mas frecuente en el mundo 
occidental. A pesar del gran número de investigaciones sobre el cáncer de colon, 
las  esperanzas de vida de estos pacientes no han mejorado mucho en los últimos 
años. Este proyecto se centra en los estadios II y III en los que la enfermedad está 
localizada en el colon o ha invadido ganglios linfáticos regionales. El tratamiento actual 
de estos pacientes es cirugía seguida de quimioterapia adyuvante, en el caso de que 
haya expansión linfática. Siguiendo estas directivas, hay pacientes que no responden 
a la quimioterapia, hay pacientes que no la necesitan puesto que la cirugía podria ser 
considerada curativa y hay pacientes que se beneficiarían de la quimioterapia pero no 
la reciben. Por eso, los dos objetivos fundamentales de este proyecto eran identificar 
marcadores moleculares de respuesta a la quimioterapia en pacientes con estadio III 
por un lado y por otro identificar marcadores pronostico en estadio II y III para clasificar 
a los pacientes más adecuadamente. 
Los tres primeros capítulos de esta tesis se centran en la farmacogenetica y la 
identificacion de marcadores predictivos. La farmacogenetica estudia el efecto de 
variaciones o polimorfismos en el ADN de genes que codifican proteinas involucradas 
en el metabolismo de determinados farmacos, en la supervivencia de los pacientes 
tratados con estos farmacos. Este trabajo se centra en proteinas involucradas en el 
metabolismo del 5-Fluorouracilo como la timidilato sintetasa, timidilato fosforilasa, 
dihidropirimidina deshidrogenasa y el ororato fosforibosil transferasa por un lado 
y por el otro en el metabolismo del oxaliplatino como ERCC1, ERCC2 y la glutation S 
transferasa Pi. Los resultados obtenidos indican que ninguno de los polimorfismos 
estudiados es un buen marcador predictivo de respuesta al tratamiento. 
Por otro lado, también se estudio el valor pronóstico de mutaciones en conocidos 
genes relacionados con el cáncer. De este modo en el capitulo cinco se expone que 
la mutación V600E en el gen BRAF caracteriza a un grupo de pacientes con mal 
pronóstico independientemente de la localización del tumor o del estadio del mismo. El 
capitulo seis describe que mutaciones en el codón 20 del gen PIK3CA también afectan 
negativamente la supervivencia de pacientes con estadio III de la enfermedad. Este 
efecto negativo no se ve en pacientes con estadio II. Además, también se ha estudiado 
el valor de p53 en el pronóstico de esta enfermedad como se expone en el capitulo 




pronostico negativo de un p53 inactivo se ve contrarrestado por la elevada expresión 
del gen caseina kinasa 1 alfa subunidad 1 (CSNK1A1). Del mismo modo, el pronóstico 
de pacientes en los que el tumor tenga un p53  inactivo y baja expresión de CSNK1A1 
es tremendamente desfavorable.
Por último, en el capitulo ocho,  presentamos las diferencias a nivel genómico de tumores 
con la mutación V600E en el gen BRAF y tumores sin esta mutación. Demostramos 
que los tumores con la citada mutación son cromosómicamente más inestables y que 
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tabellen van alle artikelen, maar ook voor je enthousiasme, je nuchterheid, je visie, je 
begeleiding, je betrokkenheid en vooral voor je vertrouwen in mij die een deur heeft 
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